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Immunity against tuberculosis depends on memory T cells following sensitisation to 
mycobacterium antigens. Clinically healthy people may be naïve to Mycobacterium 
tuberculosis (Mtb) antigens, but may also have prior vaccination with M. bovis 
bacille Calmette-Guérin, exposure to various environmental Mycobacterium species, 
or have latent tuberculosis infection (LTBI). The latter is detectable by reactivity of 
peripheral blood mononuclear cells to Mtb-specific antigens ESAT-6, CFP-10 or 
PPE68. Purified protein derivative (PPD) and Ag85A are antigens shared by most 
Mycobacterium species. Acr1 and Acr2 are Mtb ‘latency-associated antigens’ as they 
are upregulated in dormant mycobacteria. To identify immune mechanisms due to 
differing immune experience of mycobacteria, a study group of healthy young adults 
in Singapore was characterised for their reactivity to these antigens, which was then 
matched with their cytokine profiles and regulatory T cells (Tregs). In the LTBI 
group, defined by ESAT-6/CFP-10 reactivity, there was a balance of pro- and 
anti-inflammatory responses, the latter could be regulated by Tregs. 
Immunosuppressive cytokine IL10 and CD4+CD25+ Treg responses were associated 
with PPD-specific IL6 and TNFα responses, and IL12p35 was correlated with TGFβ 
expression, thus homeostatic mechanisms may be in place to limit excessive 
inflammatory responses. Induction of IFNγ responses was likely to be mediated by 
IL12 and not IL18 in this group. CD8+ Tregs could be a source of IL10 as their levels 
were correlated. Given the weak concordance between PPE68 and ESAT-6/CFP-10 
 vi
reactivity, combining these antigens was required to increase LTBI detection 
sensitivity. This combined LTBI group, especially those recently exposed (defined by 
Acr2 reactivity), most strongly expressed pro-inflammatory cytokines IL12p35 and 
IFNγ and their CD8 Tregs correlated with Foxp3 expression. This work is the first to 
demonstrate that clinically healthy subjects – often regarded as a homogenous cohort 
in TB immunity studies – exhibit a wide range of immune responses to Mtb antigens 
and these response patterns enable stratification of their anti-tuberculosis immunity 
levels. 
 vii
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CHAPTER 1 INTRODUCTION 
1.1 Project overview, aims and approaches 
Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis.  
After exposure, most infected people develop latent TB infection which could last for 
decades, with a risk of reactivation to active disease. In LTBI, host immunity prevents 
the bacteria from multiplying but they persist within host tissues (Flynn and Chan 
2005). Therefore whether the state of immunity in clinically healthy people with 
LTBI represents susceptibility or resistance to Mtb is an interesting puzzle. 
Continuous Mtb persistence in LTBI is likely to induce a chronic low grade local 
inflammatory response and prime robust memory responses to Mtb antigens. 
However, if LTBI hosts allow Mtb persistence either because the bacteria are able to 
evade immune detection, or because the hosts are susceptible to immunomodulatory 
effects of Mtb (Trajkovic et al. 2002; Singh et al. 2003), then this suggests that in 
spite of this repeated immune stimulation, the immunity in LTBI hosts fails to 
eradicate the bacteria. 
 
Tuberculin skin test (TST), which detects immune responses to a crude extract of 
protein antigens from Mtb called PPD, has been employed in the screening of LTBI 
for nearly a century (Lalvani 2007). However, this crude protein extract contains a 
mixture of mycobacterium antigens (Harboe 1981), many of which are also expressed 
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by other environmental species in the Mycobacterium genus and in the live 
Mycobacterium bovis bacille Calmette-Guérin (BCG) vaccine used for infant 
vaccination in most countries including Singapore. A family of such common 
antigens is the antigen-85 (Ag85) complex, which has homologues in most 
mycobacteria, and this results in cross-reactive immune responses. As such, prior 
BCG vaccination or environmental mycobacterium exposure also leads to PPD 
responses, resulting in low specificity of TST in detecting LTBI (Arend et al. 2001; 
Zellweger 2008). New interferon-gamma (IFNγ) release assays now available for 
more accurate detection of LTBI are QuantiFERON-TB Gold (Cellestis) and 
Tspot.TB (Oxford Immunotec) (Lalvani 2007). These assays are based on responses 
to early secreted antigenic target 6 kDa protein (ESAT-6) and culture filtrate 
protein-10 kDa protein (CFP-10), which are expressed by Mtb and very few 
environmental mycobacteria, but not in BCG (Behr et al. 1999). 
 
Due to exposure to BCG, environmental mycobacteria, or LTBI priming memory 
responses, clinically healthy people are heterogenous in their immunity to Mtb. It is of 
interest to us to understand the differences in the immunological profile of people 
with reactivity to common (shared) mycobacterium antigens versus those with 
specific Mtb exposure. We hypothesised that those with immunity primed by BCG or 
environmental mycobacteria could be more protected from Mtb than those with LTBI. 
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We used reactivity to four Mtb antigens – PPE68, Ag85A, Acr1 and Acr2 – to 
classify healthy human subjects into different groups with respect to mycobacterium 
exposure. PPE68 resides within the same Mtb genomic region which has been deleted 
from BCG, as ESAT-6 and CFP-10 (Mahairas et al. 1996; Pym et al. 2002). Hence, 
PPE68 reactivity may identify those LTBI cases missed by testing with 
ESAT-6/CFP-10. Ag85A is a major secreted mycobacterium protein common to most 
species (Wiker and Harboe 1992). Thus reactivity to Ag85A is a general indicator of 
immune priming by exposure to any mycobacteria. ESAT-6/CFP-10/PPE68 negative 
subjects who are Ag85A positive are likely to have been exposed to environmental 
mycobacteria or BCG or both. On the other hand, ESAT-6/CFP-10/PPE68 negative 
subjects who are additionally Ag85A negative are likely to have no mycobacterial 
exposure. The acr genes code for α-crystallins or small heat-shock proteins induced 
during Mtb latency. Acr1 protein is expressed in hypoxic conditions or nitric oxide 
stress (Yuan et al. 1996; Voskuil et al. 2003) while Acr2 protein is expressed upon 
heat shock, oxidative stress or following uptake by macrophages (Stewart et al. 2005). 
These conditions are believed to be associated with latency. The two α-crystallins are 
not Mtb-specific since they can be found in other mycobacteria. As such, the immune 
response to the α-crystallins has to be analysed together with immune response to 
PPE68 or ESAT-6/CFP-10. Furthermore, Acr2 is strongly recognised by healthy 
people with recent exposure to TB, in contrast to those with remote exposure 
(Wilkinson et al. 2005). Thus Acr2, in combination with Mtb-specific proteins, can be 
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used to distinguish latently infected people who have recent exposure to TB from 
those who have more remote exposure. 
 
The research strategy in this project was as follows. The above-mentioned proteins 
were expressed in Escherichia coli and purified for use as antigens to stimulate 
peripheral blood mononuclear cells (PBMC) of healthy subjects for detection of IFNγ 
responses. The subjects were classified into those with LTBI with recent or remote 
exposure to Mtb, people with previous exposure to BCG or other environmental 
mycobacteria and those with no mycobacteria exposure. Cytokine profiles and cell 
surface phenotypes of T cells from people in the different groups were studied by 
reverse transcription polymerase chain reaction (RT-PCR), enzyme-linked 
immunosorbent assay (ELISA) and flow cytometry respectively. 
 
The aims of this project were: 
1. To characterise T cell responsiveness to different mycobacterium antigens in the 
healthy Singapore community, and thereby to identify discrete groups with differing 
immune experience of Mtb and other mycobacteria 
2.  To determine the T cell phenotype and cytokine profiles associated with these 
groups 
3. To analyse how the groups differ in terms of associations between various 
immunological parameters within the Mtb response profile, and thereby to identify 
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immune mechanisms underlying responses attributable to differing immune 
experience of mycobacteria. 
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CHAPTER 2 LITERATURE REVIEW  
2.1 Immunity and immunopathology of tuberculosis 
TB is an infectious disease caused by Mtb. The most common form of TB is 
pulmonary TB in which the lungs are infected. Infection of the lungs occurs by the 
respiratory route whereby airborne aerosol droplets generated by coughing or 
sneezing from an infected person is inhaled (Falkinham 1997). Upon inhalation, the 
mycobacteria reach pulmonary alveoli in the lower respiratory tract and are taken up 
by alveolar macrophages. 
 
Approximately one third of the world’s population is infected with Mtb (Dye et al. 
1999) and 5% to 10% of the infected people progress to primary tuberculosis, while 
the rest are latently infected. In the lungs of latently infected people, mycobacterium 
replication is controlled by host immunity. Despite the presence of a robust immune 
response, mycobacteria still persist in the host (Flynn and Chan 2005). It is estimated 
that 10% of the latently infected people will have a chance of reactivation of their 
latent TB infection during their lifetime, which usually occurs when their immune 
system is compromised. 
 
Immunity to Mtb infection involves a strong T cell response that involves both CD4 
and CD8 T cells, which secrete IFNγ to activate macrophages. Cytotoxic T cells can 
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also kill infected macrophages using perforin and granulysin (Flynn and Chan 2001). 
γδ T cells (Kabelitz et al. 1990; Kabelitz et al. 1991) and natural killer cells (Zhang et 
al. 2006) also play a role in killing infected cells. The immune cells are recruited to 
the site of infection, resulting in the formation of a granuloma. Granulomas are 
aggregates of immune cells with macrophages and lymphocytes surrounding a central 
necrotic core. It is believed that granulomas serve to contain the infection and prevent 
the dissemination of mycobacteria to other sites of the body (Flynn and Chan 2005). 
Within the granuloma, activated macrophages present mycobacterial antigens to T 
cells and activate them, resulting in the production of cytokines and the subsequent 
killing of infected macrophages or activation of infected macrophages. However, Mtb 
has evolved ways of evading the immune response, one of which is the prevention of 
phagosome-lysosome fusion which results in the survival of mycobacteria in the 
phagosome (Sturgill-Koszycki et al. 1994). As such, Mtb is able to persist in the 
phagosomes of alveolar macrophages in a latent state. 
 
2.2 RD1 encoded proteins and LTBI diagnosis 
As latently infected people are healthy and do not show signs of clinical disease such 
as positive sputum culture or radiological abnormalities, LTBI is not easily detected 
clinically. By employing subtractive genomic hybridization technique (Mahairas et al. 
1996) and comparative DNA-microarray hybridization analysis (Behr et al. 1999) to 
determine differences in the genomes of virulent Mtb and M. bovis BCG,  regions of 
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difference (RD) have been identified, in particular RD1 which is deleted in all BCG 
strains and most environmental mycobacteria studied (except M. kansasii, M. szulgai, 
and M. marinum). The proteins encoded by these regions are useful as candidate 
antigens in the diagnosis of TB or LTBI since they are relatively Mtb specific. 
ESAT-6 and CFP-10, both encoded by RD1, are the most promising candidate 
diagnostic antigens. Currently, these two antigens are used in QuantiFERON-TB Gold 
(Cellestis) test which measures the amount of IFNγ released by T cells in whole blood 
when stimulated with ESAT-6 and CFP-10 (Mazurek et al. 2005; Bua et al. 2007). 
Another assay, Tspot.TB (Oxford Immunotec), also use these two proteins in an 
enzyme-linked immunosorbent spot (ELISPOT) format, measuring the number of 
antigen-specific IFNγ-secreting cells (Meier et al. 2005). 
 
Due to the lack of a gold standard for detecting latently infected people other than 
TST which has low specificity (described earlier), sensitivity of the T cell assays are 
often assessed with TB patients. ESAT-6 and CFP-10 based IFNγ release assays are 
highly sensitive, with a range of 80% to 97% of TB patients responding to ESAT-6 
and CFP-10 in low risk countries (Arend et al. 2000; Brock et al. 2001; Mori et al. 
2004; Meier et al. 2005; Ravn et al. 2005; Kang et al. 2007). These IFNγ release 
assays are also more specific than TST in diagnosing TB infection in these countries 




In countries with high TB prevalence, ESAT-6 and CFP-10 based IFNγ release assays 
have generally lower sensitivities in active TB patients (Chapman et al. 2002; Adetifa 
et al. 2007). The lowest reactivities recorded were 43% (Vekemans et al. 2001)  and 
34% (Ravn et al. 1999). A significant proportion of healthy individuals with no 
evident exposure to TB in these countries also respond to the assays (Vekemans et al. 
2001; Chapman et al. 2002; Adetifa et al. 2007), resulting in lower assay specificity in 
areas of high TB prevalence. This could be related to high levels of LTBI or 
environmental mycobacteria exposure, often found in such countries. Cross-reactive 
responses to ESAT-6 and CFP-10 are known to occur in most patients with M. 
kansasii and M. marinum infections (Arend et al. 2002; Meier et al. 2005). As such, 
not all responders to ESAT-6 and CFP-10 based IFNγ release assays in endemic 
countries have LTBI and the results have to be interpreted with caution. Moreover, a 
small proportion (up to 10%) of BCG vaccinated people respond to RD1 antigens 
(Arend et al. 2000; Brock et al. 2001; Mori et al. 2004; Ravn et al. 2005), again 
possibly related to exposure to RD1-expressing environmental mycobacteria. 
 
Responses to ESAT-6 and CFP-10 increase with increasing Mtb exposure. Gambian 
household contacts with the closest sleeping proximity to a TB patient have the 
highest percentage response and are the most likely to respond to ESAT-6 and 
CFP-10 (Hill et al. 2005; Adetifa et al. 2007). A different study, this time in a 
non-endemic country, also shows a higher percentage of ESAT-6/CFP-10 responders 
amongst people with close contact with the index case, compared to people with more 
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remote contact (Brock et al. 2004). Thus, IFNγ release assays using ESAT-6 and 
CFP-10 are relatively specific for detecting Mtb infection in asymptomatic individuals. 
 
2.3 PPE68 
Apart from ESAT-6 and CFP-10, other Mtb-specific proteins encoded by genes 
within RD1 have been characterised. PPE68 is one such protein encoded by Mtb gene 
Rv3873. PPE68 belongs to the PPE protein family of mycobacteria, which is 
characterised by a highly conserved and unique N-terminal domain of about 180 
amino acids with a proline-proline-glutamic acid (PPE) motif at amino acid position 7 
to 9 (Cole et al. 1998). This protein is not secreted and is localised to the membrane 
and cell wall of mycobacteria (Okkels et al. 2003; Demangel et al. 2004). T cell 
immunogenicity elicited by PPE68 has been demonstrated in Mtb-infected mice 
(Demangel et al. 2004) and TB patients (Okkels et al. 2003; Liu et al. 2004). 
 
The sensitivity of PPE68 has been evaluated. When PPE68 peptides pools spanning 
the whole protein are used in an ex vivo IFNγ ELISPOT assay, 53% of TB patients 
respond (Liu et al. 2004). Similar findings (42%) are noted when recombinant PPE68 
protein is used (Okkels et al. 2003). Thus, PPE68 is immunogenic in humans as 
detectable PPE68-specific T cells are induced during TB infection. However, the level 
of sensitivity is still lower than ESAT-6 and CFP-10. 
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Since RD1 is deleted in all BCG strains, BCG vaccinated healthy people with no 
known Mtb exposure should not respond to PPE68. However, 35 out of 38 BCG 
vaccinated donors in one study did not respond to PPE68, a specificity of 92.1% (Liu 
et al. 2004). Okkels and colleagues, on the other hand, find that 33 out of 40 BCG 
vaccinated donors did not respond to recombinant PPE68 protein, an even lower 
specificity of 82.5% (Okkels et al. 2003). This low specificity is largely due to one 
PPE68 epitope (amino acids 118-135) which is strongly recognised by BCG 
vaccinated donors (Okkels et al. 2003; Liu et al. 2004). This epitope is highly 
conserved with 78% to 89% identity with other PPE proteins from Mtb, BCG and 
M. leprae. It is also well conserved in unannotated proteins from M. avium, 
M. marinum, M. ulcerans and M. smegmatis (Okkels et al. 2003). Another study 
which looks at PPE68 immunogenicity in mice shows that the same epitope (amino 
acids 118-135) is mapped as an immunodominant epitope (Demangel et al. 2004). 
. 
To find a combination of specific T cell epitopes for diagnosis of TB infection, Brock 
and co-workers have evaluated the fine specificity of 4 RD encoded antigens, one of 
which is PPE68, by epitope mapping. They first identified three regions of PPE68 
protein not recognised by cells from BCG vaccinated people, after which they tested 
the sensitivity and specificity of each Mtb-specific region individually (Brock et al. 
2004). One region of PPE68 (pep2-6 corresponding to amino acids 13-69), which 
induces the highest percentage response compared to the other 2 regions, is quite 
immunogenic with a sensitivity of 46% (27 out of 59 TB patients). This region also 
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has a high specificity of 97% (Brock et al. 2004). Compared with whole PPE68 
protein, PPE68 peptides spanning amino acids 13-69 have a similar level of 
sensitivity and a much better specificity in diagnosing TB infection (Okkels et al. 
2003; Brock et al. 2004; Liu et al. 2004). In addition to being Mtb-specific and 
suitable for use in diagnosing latent TB infection, this region of PPE68 (amino acid 
13-69) is exclusively recognised by cells of two persons early upon accidental Mtb 
exposure, and not by controls with a history of TST conversion or treated TB patients 
who respond to ESAT-6 and CFP-10 (Leyten et al. 2006). Thus, this region of PPE68 
(spanning amino acids 13-69) may be associated with recent infection. 
 
Even though different study populations were investigated in the different groups, for 
instance Brock, Leyten and Okkel groups studied a healthy Danish population while 
Liu looked at the British cohort, ethnic backgrounds of TB patients, who are used in 
the assessment of PPE68 specificity, are similar. Some of the TB patients are 
Caucasians, but the majority are immigrants from Africa, South Asia, Southeast Asia 
and South America. As such, it may be expected that the higher specificity of PPE68 
peptides (Okkels et al. 2003; Brock et al. 2004; Liu et al. 2004) will also be seen in 
our study population of Southeast Asia origin. 
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2.4 Ag85A  
Ag85 complex is made up of three homologous proteins encoded by different genes 
(Wiker and Harboe 1992) – Ag85A (encoded by Rv3804c), Ag85B (encoded by 
Rv1886c) and Ag85C (encoded by Rv0129). They are major secretory proteins found 
in the culture filtrate of Mtb, but they are also found to be associated with the 
bacterial surface (Wiker and Harboe 1992).  These proteins possess mycolyl 
transferase enzyme activity which is important in the biogenesis of cord factor 
(Belisle et al. 1997) as well as fibronectin binding capability that probably helps in 
complement receptor-mediated phagocytosis of Mtb (Wiker and Harboe 1992). 
Ag85A and Ag85B are popular vaccine candidates. As DNA vaccines, they induce 
strong humoral as well as cell-mediated immunity and confer protection against Mtb 
in mice (Lozes et al. 1997; Ulmer et al. 1997; Feng et al. 2001). Ag85C, however, is 
not as effective in stimulating a robust IFNγ response (Lozes et al. 1997). Members of 
Ag85 complex are present in all mycobacteria. Using Basic Local Alignment Search 
Tool (BLAST), Ag85A from Mtb is identical in protein sequence to Ag85A from 
BCG. It is also highly similar to Ag85A from M. leprae (82%), M. ulcerans (84%), M. 
marinum (84%), M. avium (83%), M. gordonae (81%) as well as to the other 
members of Ag85 family, Ag85B (78%) and Ag85C (67%) from Mtb. This high level 
of identity in the protein sequence may result in cross-reactivity of Ag85A between 
the various mycobacterial species. 
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 Indeed, monoclonal antibodies against M. bovis BCG Ag85 complex cross-react with 
related proteins from culture filtrates of Mtb, M. kansasii, M. avium, M. xenopi, 
M. gordonae, M. fortuitum, M. phlei, and M. smegmatis (Drowart et al. 1992). T cell 
cross-reactive responses against Ag85 also occur. M. scrofulaceum-infected mice 
responded to BCG Ag85 with significant interleukin (IL)-2 and IFNγ production 
(Lozes et al. 1997). A large proportion of UK teenagers (about 70%) without prior 
BCG vaccination has positive IFNγ responses to Mtb Ag85, even though they do not 
have latent TB infection as indicated by their negative Heaf test readings (Weir et al. 
2008). This provides indirect evidence for induction of T cell responses by 
environmental mycobacteria, which cross-react with Mtb Ag85 in the majority of 
subjects. Upon BCG vaccination, all subjects respond to Mtb Ag85, which indicates 
that the BCG-induced T cell responses includes reactivity to Mtb Ag85 (Weir et al. 
2008). Since Ag85A is a widely cross-reactive antigen, Ag85A may be used as an 
indicator of mycobacterial infection or previous mycobacterium exposure but the 
exact species cannot be defined. 
 
Ag85A-specific T cell responses have been studied in different study cohorts. In 
studies performed in Belgium where TB incidence is very low, Ag85A induces T cell 
proliferation and IFNγ production by PBMCs in all healthy tuberculin-positive people, 
i.e. people with primary TB infection, and some TB patients (Huygen et al. 1988; 
Launois et al. 1994). Hence, LTBI subjects are more likely than TB patients to react 
strongly to Ag85A (Huygen et al. 1988). In a TB endemic area in Malawi, 29% of 
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healthy, non-BCG-vaccinated young adults respond to Ag85A (Black et al. 2003). In 
this cohort, it would be difficult to distinguish those who have LTBI versus those 
exposed to environmental mycobacteria. 
 
2.5 Acr1 and 2 
α-crystallins are small heat-shock proteins with molecular chaperone functions. 
Mycobacterial α-crystallins consist of three distinct classes: Acr1, Acr2 and Acr3, of 
which only two classes (Acr1 and Acr2) are found in Mtb (Stewart et al. 2005). 
 
Acr1 or HspX, encoded by Rv2031c, is a dominant protein produced during Mtb 
stationary phase, but it is undetectable during logarithmic growth (Yuan et al. 1996; 
Yuan et al. 1998). Therefore, Acr1 is most likely expressed in latent Mtb as the latent 
mycobacteria in infected people are likewise not actively replicating. Furthermore, 
acr1 gene transcription is strongly induced under hypoxic conditions or upon in vitro 
infection of macrophages (Yuan et al. 1996; Yuan et al. 1998) and following nitric 
oxide exposure (Voskuil et al. 2003). These relate to conditions in Mtb latency in vivo, 
and therefore Acr1 has become known as the Mtb latency-associated protein. 
 
Acr2 or HspR, encoded by Rv0251c, is another Mtb α-crystallin. The transcriptomes 
of Mtb grown at 45°C and 37°C have been compared, with the finding that acr2 is 
strongly upregulated following heat shock (Stewart et al. 2002). The acr2 gene is also 
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induced in naïve and activated murine macrophages, and by hydrogen peroxide and 
high dose nitric oxide exposure (Schnappinger et al. 2003). Similarly, these are also 
believed to be conditions that result in persistence of mycobacteria and as such Acr2 
is considered another latency protein. 
 
Both Acr1 and Acr2 are not Mtb-specific; mycobacterium α-crystallins have about 
15% to 25% identity with orthologues from other bacterial genera or from humans 
(Stewart et al. 2005) while the relationship between α-crystallins within the 
Mycobacterium genus is much closer. Protein BLAST shows that Mtb Acr1 is 
identical to Acr1 from many Mycobacterium species such BCG, M. gordonae, 
M. szulgai, M. genavense, M. intracellulare, M. celatum, and M. lentiflavum at amino 
acid level, and highly similar to Acr1 from M. chelonae (98%), M. avium (98%) and 
M. fortuitum (97%). Mtb Acr2 has 100% identity with BCG Acr2 and shares 73% 
identity with Acr2 from M. ulcerans, 71% identity with M. avium and 59% identity 
with M. smegmatis. This high level of homology may lead to cross-reactive immune 
responses against α-crystallins between different mycobacterium species. 
  
Acr1 induces positive T cell proliferative responses in 97% (32 out of 33) of 
BCG-vaccinated healthy people with low Mtb exposure (Wilkinson et al. 1998). 
However, only 29% (5 out of 17) of BCG-vaccinated people in another non-endemic 
country have more than 10 IFNγ secreting T cells when stimulated with Acr1 (Geluk 
et al. 2007). This difference in percentage of Acr1 responders could be due to the 
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different T cell assays employed. As the BCG vaccinated group could contain people 
with LTBI, Geluk’s study identified LTBI based on ESAT-6/CFP-10 response and 
divided the BCG vaccinated group into 2 groups. All 5 Acr1 responders (55%; 5 out 
of 9) fall in the BCG vaccinated group with positive ESAT-6/CFP-10 response while 
none of BCG-vaccinated people with negative ESAT-6/CFP-10 response respond to 
Acr1 (Geluk et al. 2007). Thus, Acr1 response is only seen in Mtb infected people 
despite the fact that Mtb Acr1 is identical to BCG Acr1 (Geluk et al. 2007). This 
specificity of Acr1 response in Mtb-infected subjects is also supported by 
observations that BCG vaccination does not induce IFNγ responses to Acr1 in infants 
2 months after vaccination (Vekemans et al. 2004). 
 
Considering that Acr1 is a ‘latency’ protein, everyone with LTBI should respond to 
Acr1. However, only 54% of TST+ people in UK (Wilkinson et al. 2005) and 67% of 
TST+ people in Netherlands are Acr1 responders (Geluk et al. 2007). From previous 
evidence that Acr1 responses is not observed in BCG-vaccinated people, the 
Acr1-specific responses in TST+ people are most likely generated by latent Mtb. As 
such, not all latently infected people who are identified based on TST response or 
ESAT-6/CFP-10 response respond to Acr1 (Wilkinson et al. 2005; Geluk et al. 2007). 
 
In TB endemic regions such as the Gambia, there is a high Acr1 response rate in 
community controls (50%; 11 out of 22) and a much higher response rate in people 
with high Mtb exposure such as household contacts (81%; 17 out of 21) and 
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healthcare workers (91%; 21 out of 23) (Vekemans et al. 2004). This further supports 
Acr1 being a ‘latency’ marker, though the possibility of cross-reactive immune 
responses induced by environmental mycobacteria cannot be totally excluded. 
 
The percentage of Acr1 responders is relatively low in TB patients (ranging from 26% 
to 77%), compared with latently infected people or healthy people with high Mtb 
exposure (Wilkinson et al. 1998; Vekemans et al. 2004; Wilkinson et al. 2005; Geluk 
et al. 2007). It has been speculated that this could be due to generalised 
immunosuppression in TB patients or that the actively replicating Mtb present in TB 
patients do not express sufficiently high Acr1 levels for induction of Acr1-specific 
IFNγ response. 
 
There are limited studies characterising expression and immunogenicity of Acr2. 
Steward and coworkers demonstrate that both Acr1 and Acr2 are expressed in lungs 
and spleens of mice the next day following intravenous administration of Mtb 
(Stewart et al. 2005). This early expression of Acr2 in Mtb infected mice is also seen 
after in vitro infection of monocytes or macrophages, which reach a peak by 24 hours 
(Wilkinson et al. 2005). As such, Acr2 which is expressed early upon Mtb infection is 
an early target for the host immune system. Indeed, in the case of a single person who 
has been accidentally exposed to virulent M. bovis, a strong response to Acr2 is 
observed within 1 week of exposure, significantly earlier than ESAT-6 and CFP-10 
response in the same person (Wilkinson et al. 2005). Acr2 is strongly recognized by 
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cattle experimentally infected with M. bovis by the second week postinfection 
(Wilkinson et al. 2005). Thus, contrary to Acr1-specific immune responses which 
seem to be only induced upon Mtb infection, cross-reactive immune responses to Mtb 
Acr2 do occur in M. bovis infection. 
 
The same group further studied Acr2 responses in TB patients and TST+ subjects, 
who are considered to have latent TB infection in the non-TB endemic country. 
Similar to Acr1 responses, not all latently infected subjects (68%) respond to Acr2 
and there is a comparably lower percentage of Acr2 responders (52%) among TB 
patients (Wilkinson et al. 2005). By dividing the latently infected group into those 
with documented recent Mtb exposure (less than 6 months) and those with no recent 
Mtb exposure, it is observed that group with recent exposure to TB has a significantly 
higher frequency of Acr2-specific IFNγ-secreting T cells than the group with remote 
exposure (Wilkinson et al. 2005). This makes Acr2 a useful antigen for identifying 
those with recent exposure to TB. 
 
2.6 T helper (Th) cells: Th1 and Th2 subsets 
About 20 years ago, Mosmann and coworkers discovered that naïve CD4 T cells, 
upon antigenic stimulation, differentiate into two distinct subsets (Mosmann et al. 
1986; Mosmann and Coffman 1989; O'Garra 1998). These two T helper subsets, 
namely Th1 and Th2, secrete characteristic cytokines and have different effector 
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functions. Many factors, such as the type of antigen presenting cells (APC), nature 
and dose of antigen, influence development of naïve CD4 T cells into Th1 and Th2 
subsets (O'Garra 1998; Glimcher and Murphy 2000). But the most potent and clearly 
defined factors which determine the fate of naïve CD4 T cells are cytokines present at 
T cell receptor ligation (O'Garra 1998; Glimcher and Murphy 2000). IL12 and IL4 are 
two important cytokines for the differentiation of Th1 and Th2 subsets respectively 
(Manetti et al. 1993). These two cytokines induce and enhance development of their 
own T helper subset while inhibiting the formation of the other T helper subset, 
resulting in the polarisation of the response to favour one subset (O'Garra 1998; 
Glimcher and Murphy 2000). 
 
2.7 Th1 cytokine IFNγ in TB 
IFNγ is the hallmark cytokine specific to Th1 cells (Mosmann et al. 1986; Mosmann 
and Coffman 1989; O'Garra 1998; Glimcher and Murphy 2000). These cytokines 
induce cell-mediated immunity by activating macrophages and delayed type 
hypersensitivity responses, therefore they are important in the protection against 
intracellular pathogens including Mtb (O'Garra 1998; Glimcher and Murphy 2000). 
 
IFNγ-deficient mice fail to inhibit Mtb replication in lungs and other organs upon Mtb 
infection (Cooper et al. 1993; Flynn et al. 1993). Even though granulomas do form, 
the granulomas rapidly become necrotic with resulting widespread tissue destruction. 
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In addition, nitric oxide synthase 2 expression is low, indicating that the macrophages 
in IFNγ-deficient mice are not activated, resulting in uncontrolled Mtb multiplication 
(Flynn et al. 1993). In humans, mutations in genes encoding for IFNγ receptor and 
signalling are associated with increased susceptibility to mycobacterium infections, 
especially non-tuberculous mycobacteria which do not commonly cause disease in the 
immunocompetent. Some children with severe mycobacterial infections have been 
found to have a mutation in IFNγR1 gene, resulting in absent or non functional 
IFNγ receptors (Jouanguy et al. 1996; Newport et al. 1996; Pierre-Audigier et al. 1997; 
Jouanguy et al. 2000; Casanova and Abel 2002). Mutation of IFNγR2 or its 
signal-transducing chain, is also associated with susceptibility to non-tuberculous 
mycobacterial infections (Dorman and Holland 1998). 
 
Some mechanisms by which IFNγ activates Mtb-infected macrophages to kill 
intracellular mycobacteria have been elucidated. In mice, activated macrophages 
induce production of reactive oxygen intermediates and reactive nitrogen 
intermediates that are toxic to mycobacteria in the phagosome (Flynn et al. 1993; 
Flynn and Chan 2001). The protective roles of reactive nitrogen and oxygen 
intermediates in Mtb infection have been demonstrated respectively in inducible nitric 
oxide synthase and cytosolic p47 gene knockout mice where increased bacterial loads 
are observed upon experimental Mtb infection (MacMicking et al. 1997; Cooper et al. 
2000). However, superoxide production which is regulated by p47 only seems to be 
protective early during Mtb infection (Cooper et al. 2000). Apart from the production 
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of toxic reactive intermediates, IFNγ also induces the expression of LRG47 which 
stimulates phago-lysosomal fusion and the subsequent killing of mycobacteria in 
infected macrophages (MacMicking et al. 2003). 
 
As IFNγ is a crucial cytokine in protection against TB, high levels of IFNγ produced 
upon stimulation of T cells with PPD or other mycobacterial antigens are associated 
with protective immunity and are often used in the identification of protective vaccine 
candidates and assessing vaccine efficacy (Vekemans et al. 2004; Nabeshima et al. 
2005; Weir et al. 2008). Many studies have investigated IFNγ levels of TB patients. It 
is generally observed that IFNγ production, upon stimulation with PPD or Mtb for 2 
to 7 days, are depressed in TB patients as compared to healthy subjects from endemic 
regions (Hirsch et al. 1999; Hussain et al. 2002) and healthy PPD+ controls (Zhang et 
al. 1995; Lee et al. 2002; Cubillas-Tejeda et al. 2003; Lee et al. 2003). IFNγ mRNA 
expression from unstimulated PBMCs is also significantly lower in TB patients than 
healthy subjects and latently infected subjects in a study in Ethiopia (Demissie et al. 
2004). IFNγ production is often increased after TB treatment and this suggests that 
Mtb infection could generate a state of anergy or suppressed IFNγ responses (Zhang 
et al. 1995; Hirsch et al. 1999). This could be because Mtb suppresses IFNγ 
production by inducing apoptosis of IFNγ-producing T cells. Significant Mtb-induced 
apoptosis is seen in TB patients, relative to healthy PPD+ controls, when PBMCs are 
incubated with Mtb for 96 hours (Hirsch et al. 1999). This accounts for the conflicting 
observation that TB patients have increased IFNγ production when a short term ex 
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vivo incubation of about 24 hours is used instead, which is higher than 
IFNγ production from healthy community controls (Winkler et al. 2005) as well as 
healthy PPD+ and PPD- individuals (Morosini et al. 2005). 
 
2.8 Th1-promoting cytokines in TB 
Other cytokines, such as IL12 and IL18, enhance IFNγ production, leading to 
increased macrophage activation and mycobacteria killing. IL12p70 is a covalently 
linked heterodimer made up to two chains, p35 kDa light chain and p40 kDa heavy 
chain (Trinchieri 2003; Trinchieri et al. 2003). IL12p40 not only associates with 
IL12p35 chain, it also associates with a p19 chain to form another heterodimeric 
cytokine IL23. As such, IL12p40 chain is often secreted in excess, at levels much 
higher than IL12p70 heterodimers (Trinchieri 2003; Trinchieri et al. 2003). IL12 is 
produced in activated cells that express both p35 and p40 chains, namely APCs such 
as monocytes and dendritic cells during infection. Apart from the p35 chain being 
produced specifically in cells that simultaneously produce p40 chain, the production 
of p35 chain is strictly controlled, resulting in a regulated production of active 
IL12p70 (Trinchieri et al. 2003). In addition to induction of Th1 responses, IL12 
enhances generation of cytotoxic T lymphocytes and natural killer cells and augments 
their cytolytic activity by inducing transcription of genes that encode for cytotoxic 
molecules such as granzyme and perforin and by upregulating expression of adhesion 
molecules (Kobayashi et al. 1989; Bloom and Horvath 1994; Trinchieri 2003). IL12 
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also acts on T cells and natural killer cells to induce IFNγ  production from these cells 
(Kobayashi et al. 1989; Kubin et al. 1994). 
 
IL18 can also trigger IFNγ production from natural killer cells and Th1 cells, and 
promote cytolytic activity of natural killer cells. Even though IL18 itself is not an 
effective IFNγ inducer, it can synergise with IL12 to induce high levels of IFNγ 
(Okamura et al. 1998). This synergistic activity is due to the upregulation of IL18 
receptors on the cell surface of IL12-stimulated T or B cells, making the cells more 
responsive to IL18 (Yoshimoto et al. 1998). IL18 contributes to the synergistic 
activity by upregulating IL12Rβ2 on naïve T cells, which enhances IL12-mediated 
signalling (Chang et al. 2000). Unlike IL12, IL18 does not induce Th1 response and it 
might even stimulate Th2 response in the absence of IL12 (Nakanishi et al. 2001). 
Therefore, IL12 and IL18 are important cytokines acting together for induction of 
effective Th1 responses. 
 
The protective roles for IL12 and IL18 in TB have been demonstrated. IL12p40 
knockout mice have marked susceptibility to Mtb while IL12p35 knockout mice have 
moderate susceptibility with lower bacterial loads in their lungs and spleens as 
compared to IL12p40 knockout mice but higher bacterial loads than control mice 
(Cooper et al. 2002). IL12p40 knockout mice shows higher mortality compared to 
IL12p35 knockout mice. The higher resistance to Mtb in IL12p35 knockout mice is 
attributed to the protective effects of IL23 that has similar functions as IL12 in 
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inducing IFNγ (Cooper et al. 2002). IL12 is also required to maintain effector or 
memory Th1 cells and thus maintain prolonged IFNγ responses for protection against 
TB (Stobie et al. 2000). In humans, patients with complete IL12p40 chain or 
IL12p40Rβ1 deficiency have impaired IFNγ production and are more susceptible to 
mycobacterial infections, though with a milder clinical phenotype compared to 
patients with complete IFNγ deficiency (Casanova and Abel 2002). This further 
demonstrates the protective role of IL12 in the generation of an effective Th1 
response and the existence of IL12-independent pathways of IFNγ production. IL18 
knockout mice have impaired IFNγ production and show bigger lung granulomas as 
well as higher Mtb counts (Sugawara et al. 1999), but they have relatively lower 
bacterial loads than IL12p40 deficient mice (Kinjo et al. 2002). This suggests that 
IL12 or IL23 is more crucial in protection against Mtb infection, as IL18 is only able 
to potentiate IFNγ production. 
 
In general, there is general depression of Th1 related cytokines IL12 and IL18 with 
correspondingly decreased IFNγ production in TB patients. Depressed IL12p40 and 
IFNγ mRNA and cytokine levels have been observed in TB patients compared to 
healthy community controls in endemic areas (Demissie et al. 2004) and 
PPD+ healthy controls (Song et al. 2000). The production of the two cytokines is 
significantly correlated in TB patients and this supports the role of IL12 in driving 
Th1 responses leading to IFNγ production (Song et al. 2000). When the same group of 
investigators further investigated cytokine levels in different types of TB patients 
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including newly diagnosed, recurrent pulmonary TB patients and TB patients with 
unsuccessful treatment, they found that only those with recurrent TB had depressed 
IL12p40 levels with corresponding depressed IFNγ levels (Lee et al. 2003). However, 
reduced IFNγ is not seen in patients with multidrug-resistant TB (Lee et al. 2002). As 
IL12p40 is not significantly correlated with IFNγ production in the latter study, there 
might be dysregulated production of IL12 in this group of TB patients with 
multidrug-resistant TB (Lee et al. 2002). TB patients have lower IL18 production with 
corresponding lower IFNγ production when compared to PPD+ healthy people 
(Vankayalapati et al. 2000; Vankayalapati et al. 2003). IL18 regulates IFNγ 
production in TB as there is decreased IFNγ production upon anti-IL18 treatment and 
enhanced IFNγ production upon addition of recombinant IL18 (Vankayalapati et al. 
2000). 
 
2.9 T helper 2 cytokines in TB 
Cytokines produced by Th2 cells can include IL4, IL5, IL6, IL10 and IL13 (O'Garra 
1998; Glimcher and Murphy 2000). IL4, together with IL5, stimulates antibody 
production by B cells and induces isotype switching to IgE and IgG1 (Purkerson and 
Isakson 1992). IL10 also acts on B cells to induce their proliferation and 
differentiation as well as isotype switching to IgG1 (Moore et al. 2001). In addition, 
Th2 cytokines, IL4 and IL10, are able to inhibit development of Th1 cells and Th1 
cytokine production (Fiorentino et al. 1991; O'Garra 1998; Glimcher and Murphy 
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2000; Moore et al. 2001). This further polarises to a Th2 response and the subsequent 
generation of an effective humoral immunity. IL6 also aids in the induction of 
humoral response by inducing terminal differentiation of B cells into 
antibody-forming plasma cells (Muraguchi et al. 1988). 
 
Some Th2 cytokines, such as IL6 and IL10, have other functions unrelated to the 
generation of humoral responses. Apart from inhibiting Th1 cytokine production, 
IL10 has other immunosuppressive and anti-inflammatory activities such as the 
inhibition of APC activation and function in terms of cytokine production, nitric oxide 
production in macrophages and expression of major histocompatibility complex 
(MHC) class II and costimulatory molecules on APC cell surfaces (Moore et al. 
2001). IL6 is a pleiotropic cytokine with a wide range of biological activities in T cell 
development and function, generation of cytotoxic T lymphocytes and induction of 
their cytolytic activity, in haematopoiesis as well as in the synthesis of acute phase 
proteins (Le et al. 1988; Ramadori et al. 1988; Galandrini et al. 1991; Bernad et al. 
1994). As such, IL6 also has pro-inflammatory activities. 
 
The protective role of IL6 in TB is demonstrated by intravenously infected IL6 
knockout mice which have higher bacterial loads and a shorter survival time (Ladel et 
al. 1997). An early increase in bacterial load is seen in the lungs of the IL6 knockout 
mice infected by low dose aerosol, with a concurrent delay in IFNγ production. 
However, the knockout mice are able to control the infection and develop protective 
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memory responses (Saunders et al. 2000). Therefore, with the latter route which 
mimics natural infection, the protective effects of IL6 are limited to the initial stage of 
infection. These protective effects are most likely attributed to its effect in the 
initiation and development of both innate and adaptive immunity with production of 
protective cytokine IFNγ (Ladel et al. 1997; Saunders et al. 2000). 
 
TB patients generally have high IL6 levels upon stimulation with PPD compared to 
community controls in endemic areas (Hussain et al. 2002) and PPD+ healthy subjects 
(Lee et al. 2003). IL6 produced in TB patients may exert its protective effects by 
inducing both innate and adaptive immune responses. However, IL6 may also have 
inhibitory effects as demonstrated by in vitro studies where there is suppressed T cell 
proliferation and activation by macrophages exposed to M. bovis BCG or M. avium 
(VanHeyningen et al. 1997). Reduced ability of macrophages to respond to IFNγ has 
been attributed to the selective inhibition of a subset of IFNγ responsive genes by 
Mtb-induced IL6 (Nagabhushanam et al. 2003). 
 
IL4 may be involved in TB immunopathology. IL4 mRNA expression is correlated 
with disease severity with high levels of IL4 seen in TB patients with more severe 
disease (Seah et al. 2000; Dheda et al. 2005). However, some studies fail to detect 
raised IL4 levels in TB patients (Zhang et al. 1995; Demissie et al. 2004), which may 
be related to difficulty in detecting low IL4 concentrations and mRNA copy number, 
the existence of IL4 splice variant which confounds IL4 measurements, and the 
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tendency to polarise to Th1 responses upon mycobacterium antigen stimulation of 
PBMCs (Rook et al. 2004). With the development of a novel nested RT-PCR 
technique which overcomes these technical problems, IL4 levels are found to be 
elevated in unstimulated PBMCs of TB patients compared to PPD+ healthy subjects 
(Seah et al. 2000). By employing another sensitive and well validated assay, IL4 
levels are similarly found to be higher in TB patients (Dheda et al. 2005). 
 
Some mechanisms of IL4 in mediating disease progression have been elucidated. A 
recent discovery demonstrates that macrophages can be alternatively activated by IL4 
or IL13, with an reduced production of nitric oxide synthase 2, downregulation of 
pro-inflammatory cytokines tumour necrosis factor alpha (TNFα), IL6 and IL1, 
increased production of immunosuppressive cytokine transforming growth factor beta 
(TGFβ) and increased expression of transferrin receptor and iron storage protein 
bacterioferritin (Kahnert et al. 2006; Rook 2007). All these effects of alternative 
macrophage activation oppose the protective actions of IFNγ and support 
mycobacterium persistence in the phagosome. For instance, with reduced nitric oxide 
synthase 2 and resulting reactive nitrogen intermediates production, intracellular Mtb 
is exposed to less nitrosative stress and killing. By increasing iron availability through 
increased expression of transferrin receptor and iron storage protein, mycobacterium 
replication and persistence in macrophages is supported. 
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IL4 also mediates sensitivity to the toxic effects of TNFα demonstrated by the 
absence of toxicity of TNFα in TB-infected IL4 knockout mice and restoration of 
TNFα toxicity with the administration of recombinant IL4 (Hernandez-Pando et al. 
2004). As IL4 mediates sensitivity to the pro-inflammatory effects of TNFα, there is 
more severe immunopathology with increased fibrosis in wild type mice when 
compared to IL4 knockout mice (Hernandez-Pando et al. 2004). One mechanism in 
which IL4 changes toxicity of TNFα is by reducing TNFα-induced apoptosis through 
the release of increased levels of soluble TNFα receptors (Brodbeck et al. 2002). 
Apoptosis induction is crucial in protection against Mtb as it limits the release of 
intracellular components and subsequently, the spread of mycobacterial infection. 
This apoptotic mechanism is normally evaded by virulent Mtb which also releases 
increased levels of soluble TNFα receptors (Fratazzi et al. 1999). By releasing soluble 
TNFα receptors in the same way (Brodbeck et al. 2002), IL4 inhibits TNFα induced 
apoptosis and this is likely to result in a corresponding increase in tissue necrosis and 
severe inflammation. 
 
In addition, IL4 induces development of antigen-specific CD4+CD25+ regulatory T 
cells from peripheral CD4+CD25- T cells (Skapenko et al. 2005). IL4-induced Tregs 
resemble naturally occurring Tregs phenotypically and functionally: they express high 
levels of Forkhead box P3 (FoxP3), glucocorticoid-induced TNF receptor 
family-related protein and cytotoxic T-lymphocyte antigen 4, and inhibit effector T 
cells in a contact dependent but cytokine independent manner (Skapenko et al. 2005). 
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All these effects caused by IL4 such as alternative activation of macrophages, 
increased toxic effects of TNFα, as well as induction of Tregs, increases survival of 
mycobacteria in macrophages and leads to immunopathology in the lungs. 
 
2.10 Natural regulatory T cells and immunoregulatory cytokines in TB 
Regulatory T cells are a specialised subpopulation of T cells with immunosuppressive 
activity. They are important in preventing excessive immune responses towards 
pathogens during infection, which could result in severe inflammation and tissue 
damage (Mills 2004). 
 
Different types of Tregs have been described based on their origin, generation and 
mechanism of action. Two main subsets have been identified, one of which is the 
naturally occurring CD4+CD25+ Tregs which develop in the thymus and suppress 
immune responses of self-reactive T cells in the periphery (Bluestone and Abbas 2003; 
Mills 2004). In contrast, inducible Tregs are generated from CD4+CD25- T cells in the 
periphery upon encounter with antigen presented by APCs in the presence of 
immunosuppressive cytokines (Bluestone and Abbas 2003; Mills 2004). Inducible 
Tregs include T regulatory 1 cells that secrete IL10 and Th3 cells that secrete TGFβ. 
In addition to these well-characterised CD4+ Tregs, CD8+ Tregs with 
immunosuppressive activities have also been identified (Mills 2004; Joosten et al. 
2007). 
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Up till now, studies of natural Tregs are hindered by lack of a definitive Treg marker. 
Though Tregs express high levels of CD25, CD25 is also an activation marker for T 
cells and activated effector T cells also express CD25 (Sakaguchi et al. 1995; 
Baecher-Allan et al. 2001; Mills 2004). Other alternative putative markers for natural 
Tregs include glucocorticoid-induced TNF receptor and intracellular expression of 
FoxP3 (Shimizu et al. 2002; Fontenot et al. 2003; Hori et al. 2003). FoxP3 is the most 
promising natural Treg marker as FoxP3 is required for the development of natural 
Tregs and transfection of CD4+CD25- T cells with foxp3 gene converts these naïve T 
cells into Tregs with immunosuppressive activity (Hori et al. 2003). There remains 
some conflict over whether infection-induced Tregs express the same markers. 
 
It is thought that natural CD4+CD25+ Tregs are involved in peripheral tolerance and 
only recognise self antigens, but there is evidence that these Tregs can also inhibit 
foreign antigen-specific immune responses in infectious diseases, especially from 
studies of schistosoma and leishmania infection (Belkaid and Rouse 2005; Suffia et al. 
2006). In TB, natural CD4+CD25+ Tregs accumulate at sites of disease and are also 
elevated in the blood of TB patients (Guyot-Revol et al. 2006; Ribeiro-Rodrigues et al. 
2006; Chen et al. 2007). These natural CD4+CD25+ Tregs in TB patients are found to 
have antigen-specific immunosuppressive activities, as depletion of CD4+CD25+ cells 
results in increased Mtb or Mtb antigen-specific IFNγ production or increased 
frequencies of IFNγ-secreting cells (Guyot-Revol et al. 2006; Ribeiro-Rodrigues et al. 
2006). Recently, Hougardy and colleagues further demonstrate that depletion of 
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CD25high T cells leads to the almost complete disappearance of CD4+CD25highFoxP3+ 
T cells, a subset that represents natural Tregs most accurately, with abolishment of 
Mtb antigen-specific immunosuppression (Hougardy et al. 2007). 
 
IL10 and TGFβ are two immunosuppressive cytokines that can be secreted by Tregs 
to mediate immunosuppression. IL10 was first described as cytokine synthesis 
inhibitory factor that inhibits IFNγ production by Th1 cells in mice (Moore et al. 
2001). It can also act on T and B cells, APCs and neutrophils and suppress their 
functions. The most direct effect of IL10 on T cells is through the inhibition of 
monocyte or macrophage function, resulting in reduced production of inflammatory 
cytokines, such as IL1, IL6 and TNFα, suppressed surface expression of MHC class II 
molecules, and subsequent reduced T cell proliferation (de Waal Malefyt et al. 1991; 
de Waal Malefyt et al. 1991). TGFβ is another potent immunosuppressive cytokine 
which overlaps with many IL10 functions, including T cell suppression, modulation 
of pro-inflammatory cytokines, and interference with antigen presentation (Wahl 
1992). 
 
Many studies demonstrate elevated IL10 cytokine production in TB patients 
compared to healthy community controls in endemic areas (Hirsch et al. 1999) and 
healthy PPD+ controls (Song et al. 2000; Lee et al. 2002). As such, IL10 may be 
involved in the generalised immunosuppression seen in TB patients. Indeed, 
PPD-specific anergy in TB patients is associated with IL10-producing cells or 
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inducible T regulatory 1 cells (Boussiotis et al. 2000). This subset of T regulatory 1 
cells is able to suppress antigen-specific IFNγ responses as neutralisation of IL10 by 
IL10-specific antibodies increases PPD-specific IFNγ production by T cells from 
anergic patients (Boussiotis et al. 2000). In a study of natural Tregs in TB, although 
there is increased IL10 and TGFβ mRNA expression in PBMCs of TB patients, these 
cytokines are not preferentially expressed by CD4+CD25+ Tregs (Guyot-Revol et al. 
2006). These two immunosuppressive cytokines are also secreted by other cell types 
other than natural CD4+CD25+ Tregs, such as inducible T regulatory 1 and Th3 subset. 
 
The role of natural Tregs in TB is not clear. However, natural Tregs are often found in 
chronic infections, such as TB and leishmaniasis (Belkaid and Rouse 2005). When 
natural Tregs are depleted or the function of natural Tregs is impaired, complete 
eradication of pathogens is achieved, but the host is more prone to reinfection which 
is possibly due to the ineffective maintenance of effector cells (Belkaid et al. 2002; 
Belkaid and Rouse 2005). On the other hand, natural Tregs limit robust immune 
responses and resulting immunopathology (Aseffa et al. 2002; Belkaid and Rouse 
2005). Thus the balance of Tregs and effector cells is important as it can determine 
whether there is complete pathogen elimination by immune responses, pathogen 
persistence in latency or pathogen replication and activation of disease. As Mtb is 
found to induce inhibitory cytokine IL10 production by monocytes and T cells, Mtb is 
likely to evade host immunity by downregulating costimulatory molecules on 
macrophages and impairing cytotoxic T cell lytic activity (de la Barrera et al. 2004). 
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Therefore, Mtb may be making use of Tregs to evade robust host responses and 
prevent their own eradication, leading to persistent infection in the majority of 
infected individuals. 
 
Other than natural Tregs, an inducible CD8+ human Treg subset with suppressive 
activity has been described by Joosten and coworkers (Joosten et al. 2007). This 
subset can be induced upon BCG stimulation of PBMCs from subjects who respond 
to PPD, or subjects who have been primed in vivo. The majority of CD8+ T cells 
express CD25 and lymphocyte activation gene 3 (LAG3), which has also been 
described as a transmembrane protein expressed by (Tregs) that inhibits activation of 
dendritic cells by binding MHC class II molecules on APCs (Joosten et al. 2007; 
Liang et al. 2008). CD8+LAG3+ cells also express degranulation marker CD107a and 
granulysin (Joosten et al. 2007), suggesting that cytotoxicity may be one 
immunosuppressive mechanism of this Treg subset. This subset mediates suppression 
in part by CC chemokine ligand 4 and is detectable in lymph node granulomas in 
Mtb-infected individuals (Joosten et al. 2007), suggesting that its presence is probably 
associated with Mtb persistence in lymph nodes. Similar to natural Tregs, this CD8+ 
Treg subset can have beneficial or detrimental effects in suppressing excessive 
inflammatory responses or promoting Mtb persistence. 
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2.11 Other T cell subsets in TB 
Apart from the conventional CD8 and CD4 T cells which recognise peptide antigens 
presented by MHC class I and II molecules respectively, non-conventional T cell 
subsets, such as γδ T cells specific for small phospholigands and CD1 restricted T 
cells that recognise glycolipids abundant in the mycobacterium cell wall, have a 
significant role in protective immunity to TB. CD1 restricted T cells can contribute to 
protective immunity by the production of IFNγ (Sieling et al. 1995), and killing of 
Mtb-infected macrophages (Stenger et al. 1997). Like CD1 restricted T cells, γδ T 
cells secrete the protective cytokine IFNγ and exert cytotoxic effects on Mtb-infected 
cells in the presence of mycobacterial phosphoantigens and IL2 (Hayday 2000). 
Additionally, IFNγ produced by γδ T cells are able to condition dendritic cells for 
effective priming of CD8 T cell response against Mtb (Caccamo et al. 2006), which 
further supports a protective role for γδ T cells in Mtb infection. 
 
A third subset of T helper cells Th17, apart from Th1 and Th2 subsets, has been 
discovered. Th17 cells mainly produce IL17 which is involved in mediating 
inflammation and neutrophil recruitment to mucosal sites (Ye et al. 2001; Aujla et al. 
2007). The efficient generation of Th17 cells is dependent upon the presence of IL23 
during the initial priming. By knocking out IL12p19 in mice, which is one of the two 
subunits of IL23, Th17 responses are impaired but the inflammatory responses and 
development of mycobacterium granuloma is not significantly altered (Khader et al. 
2005), which demonstrates that Th17 cells have a limited role in the initial granuloma 
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formation. Recently the same group went on to show that Th17 cells, which are 
induced upon vaccination, do have a protective effect against Mtb, probably in the 
recruitment of protective Th1 cells, as the expression of CXCL chemokines and Th1 
cells are reduced upon IL17 depletion during Mtb challenge (Khader et al. 2007). 
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CHAPTER 3 MATERIALS AND METHODS 
3.1 Production and purification of recombinant proteins (Acr1 and Acr2)  
3.1.1 Bacteria and plasmids  
Escherichia coli DH5α was used for cloning while E. coli BL21 (DES) pLysS or E. 
coli BL21-CodonPlus® (DES)-RIPL (Stratagene) was used for protein expression. 
Both strains were grown in Luria-Bertani (LB; Difco Laboratories) broth or solid 
media, and supplemented with 100 μg/ml of ampicillin (Sigma) when required for 
plasmid maintenance. 
 
Figure 1. Plasmid map of pET-11a vector (Novagen. Technical Literature TB042. 
http://www.merckbiosciences.com/docs/NDIS/TB042-000.pdf) 
 
pET-11a vector (Novagen; Fig 1), which was used for protein expression, contains lac 
I gene that codes for the lac repressor. Induction by the addition of isopropyl 
 39
thiogalactoside (IPTG) displaces the lac repressor from the lac operator, so that T7 
RNA polymerase, produced in E. coli BL21 strains, binds T7 promoter and induces 
gene transcription. Ampicillin resistance gene present in the vector acts as a positive 
selection marker while the polyhistidine tag sequence at the N-terminal of the 
recombinant protein aids in its purification and detection. 
 
3.1.2 Amplification of genes from Mtb genomic DNA by PCR 
Gene sequences encoding Mtb Acr1 (Rv2031c) and Acr2 (Rv0251c) were derived 
from Tuberculist (http://genolist.pasteur.fr/TubercuList), which is based on the 
published Mtb H37Rv genome sequence (Cole et al. 1998). Primers flanking the 
coding regions were designed with the addition of appropriate restriction enzyme sites 
to 5’ ends (appendix section 7.1). PCR amplification was performed in a 50 μl 
reaction comprising 0.2 μl Expand High Fidelity Taq DNA polymerase (Roche), 5 μl 
10x PCR buffer, 3 μl 25mM MgCl2, 2 μl 10mM dNTPs, 3 μl Q-solution (Qiagen), 
1 μl each of 10mM gene-specific primers, 10 ng of Mtb genomic DNA template and 
topped up with RNase-free water. Initial denaturation at 98°C for 10 minutes was 
followed by 35 cycles of denaturation at 96°C for 30 sec, annealing at 55°C for 30 sec 
and elongation at 72°C for 30 sec. A final elongation step at 72°C for 10 minutes was 
carried out. Sizes of the amplicons were confirmed on electrophoresis on 1% agarose 
gel, and amplicons purified using PCR product purification kit (Qiagen), according to 
the manufacturer’s protocol, to remove excess dNTPs, primers and salts. The purified 
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amplicons were vacuum concentrated for 10 min to remove ethanol traces which may 
inhibit enzyme reactions. 
 
3.1.3 Cloning PCR amplicons into pET-11a vector  
Purified PCR amplicons were cloned into pET-11a vector as follows. Acr2 PCR 
amplicon and vector were sequentially digested, first with BamHI overnight at 37°C 
in a 100 μl reaction mix containing 10 μl of EcoRI buffer, 1 μl of bovine serum 
albumin (BSA), 0.5 μl of BamHI. Subsequently, 0.5 μl of EcoRI was added for 2 
hours at 37°C.  For Acr1 cloning, reactions with NcoI and BamHI were performed in 
BamHI buffer simultaneously overnight at 37°C. All restriction enzymes were from 
New England Biolabs (NEB). The reaction products were column-purified (PCR 
product purification kit, Qiagen) to remove small DNA fragments, and trace ethanol 
was removed in the vacuum concentrator as above. 
 
The 10 μl ligation reaction included 50 ng of vector fragment, 25 ng of PCR amplicon 
fragment, 1 μl of T4 10x ligation buffer (Roche) and 1 μl of T4 ligase (Roche). The 
reaction mixture was incubated at 14°C for 5 hours. The cloned pET-11a vectors were 




Figure 2. Plasmid maps of pAcr1 and pAcr2 created using Sci Ed Central Clone Manager 
version 6 indicating polyhistidine and haemagglutinin tags in front of gene insert (Lac: lac 
operon) 
 
3.1.4 Preparation of E. coli competent cells 
One colony of E. coli was inoculated into 5 ml of LB broth and grown at 37°C 
shaking overnight. A 1:100 dilution was made in 200 ml of broth, with 4 ml of 
MgSO4 added, and further incubated at 37°C, shaking at 250 rpm, until the OD600 
reached 0.3 to 0.4. The bacteria were then put on ice for 15 minutes, transferred to a 
50 ml chilled centrifuge tube, and centrifuged at 1600 x g for 10 minutes at 4°C. The 
medium was discarded and the cells resuspended in 10 ml of ice-cold CaCl2 solution. 
The bacteria were centrifuged and resuspended in a fresh 10 ml of ice-cold CaCl2 
solution for 30 minutes. The final bacterial pellet was resuspended in 8 ml of ice cold 
CaCl2 solution and kept at -80°C. 
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3.1.5 Transformation of E. coli 
For transformation, 1 μg of pAcr1 or pAcr2 was added to 1 x 107 E.coli DH5α while 
20 ng of vector was required for 1 x 107 E.coli BL21 (DE3) pLysS. As for E.coli 
BL21-CodonPlus® (DES)-RIPL, 50 ng of vector was added to a 100 μl aliquot of 
competent bacteria as recommended by the supplier (Strategene). 
 
pAcr1 was used to transform E.coli BL21-CodonPlus® (DES)-RIPL, according to 
manufacturer’s protocol. First, 2 μl of diluted (1:10) L10-Gold β-mercaptoethanol 
was mixed with 100 μl of thawed competent cells and the mixture was incubated on 
ice for 10 minutes. Next, 50 ng of vector was added to the competent cells on ice for 
30 minutes. Cells were treated at 42°C for 20 seconds and immediately back into ice 
for 2 minutes. Lastly, 900 μl of warm LB broth was added to the tube for 90 minutes 
incubation at 37°C, shaking at 250 rpm, to allow the bacteria to express the gene. 
pAcr2 was used to transform E.coli BL21 (DE3) pLysS by a similar method as 
follows. Ten million competent cells were thawed rapidly, and 1 μg of vector was 
added. The mixture was mixed and incubated on ice for 15 minutes. After heat-shock 
and ice treatment as above, 200 μl of LB broth was added for incubation, as for Acr1 
expression. 
 
After incubation, the transformed cells were cultured on LB/ampicillin agar overnight 
at 37°C. Single isolated colonies (individual clones) were separately grown in 6 ml of 
 43
LB/ampicillin broth to OD600 of 0.6 to 0.8, then plasmids extracted from each clone 
for restriction analysis. Concurrently, 25% glycerol stocks of each clone were stored. 
 
3.1.6 Plasmid extraction (‘mini-prep’) 
All centrifugation steps were carried out at 15,000 x g at 4°C unless otherwise stated. 
The transformants (OD600 = 0.6 to 0.8) were first centrifuged at 2500 x g for 10 
minutes at 4°C and cells resuspended in 200 μl of Resuspension solution (appendix 
section 7.2.1). Sequentially, 200 μl Cell Lysis solution (appendix section 7.2.2) and 
200 μl of Neutralisation solution (appendix section 7.2.3) were added, with gentle 
mixing by inverting the tubes 5 times in between. After 10 minutes centrifugation, 
supernatants were collected and 300 μl of isopropanol added with vigorous mixing to 
precipitate the plasmid. After further 10 minutes of centrifugation, the pellet was 
washed twice in 1 ml 70% ethanol, then dried in a vacuum concentrator for 15 
minutes, followed by plasmid reconstitution in 30 μl of sterile distilled water. 
 
3.1.7 Plasmid analysis 
The plasmids extracted were analysed using their respective restriction enzymes (refer 
to Section 3.1.3) at 37°C for 2 hours in a 20 μl reaction comprising 3 μl of plasmid, 2 
μl enzyme buffer (NEB), 0.2 μl BSA, 0.5 μl each of two restriction enzymes and 
topped up with sterile distilled water. The reaction was then analysed by agarose gel 
electrophoresis to confirm the presence of the cloned gene. 
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3.1.8 DNA sequencing 
Sequencing was performed to confirm the exact gene sequence of the cloned plasmids 
pAcr1 and pAcr2. A 10 μl DNA sequencing reaction comprised 4 μl of BigDye 
Terminator Ready Reaction Mix (version 3.1, Applied Biosystems), 25 to 100 ng of 
plasmid, 1 μl of 1μM forward and reverse primers complementary to plasmid 
sequence before and after cloning sites (appendix 7.3) and topped up with DNase free 
water. The sequencing reaction involved 25 cycles of denaturation at 96°C for 30 
seconds, primer annealing at 55°C for 15 seconds and extension at 60°C for 4 minutes 
in a thermocycler. 
 
To purify the extension products and remove excess primers and terminators, the PCR 
amplicon added to 80 μl of ethanol-sodium acetate solution (3 μl of 3M sodium 
acetate at pH 4.6, 62.5 μl of molecular grade 95% ethanol and 14.5 μl of water) at 
room temperature for 15 minutes to precipitate extension products, followed by 10 
minutes centrifugation and washing of the pellet with 500 μl of 75% ethanol. The 
supernatant was carefully removed and trace ethanol in the pellet evaporated after 10 
minutes in a vacuum concentrator. Capillary DNA sequencing was performed in an 
ABI PRISM® 3100 genetic analyser (Applied Biosystems), and the chromatograms 
analysed by comparison against the Mtb H37Rv genome (Tuberculist). 
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3.1.9 Protein expression in E. coli 
E. coli transformants were incubated in 2 tubes of 6 ml LB/ampicillin broth, with 
moderate shaking at 37°C overnight. The bacterial cultures were diluted 1:100 into 2 
flasks of 600 ml LB/ampicillin broth, followed by 2 to 3 hours of shaking at 250 rpm 
at 37°C until the OD600 reached 0.4 to 0.8. Thereafter, 2mM of IPTG was added for 
another 2 hours to the growing culture to induce plasmid gene transcription and 
protein expression. Different concentrations of IPTG and induction times were tested 
to optimise conditions for maximal protein expression. The 1.2 litre cultures in 2 
separate flasks were combined and cell pellets collected after centrifugation at 3,400 x 
g for 10 min at 4°C. 
 
3.1.10 Lysis of E. coli cells 
Bacteria were suspended in 10 ml of lysis buffer (20mM Tris HCl, pH 7) on ice, then 
200 μl of 50x protease inhibitor (appendix section 7.4) and 4 mg of lysozyme (Sigma) 
were added with constant stirring for 10 minutes. Next, 20 mg of deoxycholic acid 
(Sigma) was added, stirring for another 10 minutes. The mixture was removed from 
ice and 200 μl of 1 mg/ml DNase (Sigma) as well as 25 μl of 2mM MgCl2 were added 
into the mixture with constant stirring for 30 minutes. The lysate in a sealed tube was 
subjected to 3 cycles of sonication (20 seconds each) using a cup-horn sonicator 
(Vibra-cell Ultrasonic processor, Sonics) and reducing agent 20mM 
β-mercaptoethanol was added before centrifuging at 18,000 x g for 1 hour. The 
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resulting supernatant was collected and stored at -80°C until protein purification could 
be performed. 
 
3.1.11 Fast performance liquid chromatography (FPLC) purification of His-
tagged proteins by affinity chromatography 
The FPLC system (Pharmacia) was used to aid purification of polyhistidine tagged 
recombinant proteins by affinity chromatography. First, Econo-Column 
chromatography column (Biorad) containing 6 ml of Ni-NTA Superflow (Qiagen), a 
nickel charged resin, was assembled onto the FPLC system and equilibrated with 5 
column volumes of Lysis Buffer (appendix section 7.5.1) with a solvent velocity of 1 
ml/min until the baseline was reached. Any protein which passed through the column 
was detected by a UV monitor with an attached chart recorder. The bacterial lysate 
was filtered through a 0.45 μm filter before applying to the column. The immediate 
eluate (‘flowthrough’ fraction) was collected for analysis and the column was washed 
with Lysis Buffer until baseline was reached. This ‘washthrough’ fraction was also 
collected. The column was next washed with Wash Buffer (appendix section 7.5.2) 
until baseline was reached and the Wash Buffer ‘washthrough’ was also collected for 
analysis. Elution of polyhistidine-tagged proteins was performed by applying 5 
column volumes of Elution Buffer (appendix section 7.5.2 to 7.5.4) with increasing 
imidazole concentrations (150mM to 250mM; Sigma). Eluted fractions were collected 
for further analysis. 
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3.1.12 Protein electrophoresis (SDS-PAGE) 
Protein fractions from FPLC were analysed using sodium dodecyl sulphate 
polyacrylamide gel electrophoresis (SDS-PAGE) which separates protein by 
molecular size. A 12% polyacrylamide gel (appendix section 7.6.1 to 7.6.2) was used 
for protein analysis since Acr1 and Acr2 have molecular weights of 19 kDa and 21 
kDa respectively. First, 2 μl of 6x SDS buffer (appendix section 7.6.3) was added to 
10 μl of protein and boiled at 100°C for 5 minutes to denature proteins and all 12 μl 
were loaded into each well. SeeBlue® Plus2 pre-stained standard marker (7 μl, 
Invitrogen) was also loaded. The gel was run at 100V for 90 minutes in Running 
Buffer (appendix section 7.6.4) using Mini-Protean® 3 Electrophoresis cell (Biorad). 
Subsequently, the gel was stained with Coomassie Blue Staining solution (appendix 
section 7.6.5) on a shaking platform for 1 hour. Destaining of gel was performed with 
Gel Destaining solution (appendix section 7.6.6) with continuous shaking overnight. 
Finally, the gel was visualised under visible light with a gel documentation system 
(Chemigenus, Syngene). 
 
3.1.13 Western blot 
Protein samples were first separated using SDS-PAGE. The stacking gel was removed 
and the separating gel was soaked in Transfer Buffer (appendix section 7.7.1) for 10 
minutes. A Hybond-P polyvinylidene difluoride membrane (Amersham Biosciences) 
was cut to size and treated with 100% methanol for 10 seconds. The membrane was 
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then washed with distilled water and soaked in Transfer Buffer for 10 minutes. Fibre 
pads and filter paper were also equilibrated in Transfer buffer. 
 
The Mini Trans-Blot® cell (Biorad) was assembled and protein transfer from gel to 
membrane performed at 350mA for 90 minutes at 4°C, then the gel was stained with 
Coomassie Blue to check for complete transfer. The membrane was removed for 
immunodetection of recombinant proteins. All incubations were performed on a roller 
mixer unless otherwise stated. The membrane was first blocked with 5% skim milk 
and 1% BSA in Tris-buffered saline Tween-20 (TBST; appendix section 7.7.2) for 1 
hour. Next, the membrane was incubated overnight with 10 μl of 500 μg/ml 
monoclonal anti-polyhistidine antibody (R&D systems) in 6 ml of 5% skim 
milk/TBST. The membrane was then washed with 30 ml of 1% skim milk/TBST for 
10 minutes. This wash step was repeated two more times. Lastly, the membrane was 
incubated with secondary antibody, 1.5 μl of ECL horseradish peroxidase linked 
anti-mouse IgG (Amersham Biosciences) diluted in 6 ml of 5% skim milk/TBST, for 
1 hour, after which the membrane was given three 10 minutes wash steps with 30 ml 
of TBST each time. 
 
Detection of proteins was performed with ECL PlusTM Western Blotting analysis 
system (Amersham Biosciences). The membrane was incubated with the detection 
reagents from the kit for 1 minute, drained of the detection reagents and exposed to 
HyperfilmTM ECL autoradiography film (Amersham Biosciences) for 5 to 10 minutes 
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The Slide-A-Lyzer® dialysis cassette with 2 kDa molecular weight cutoff (Pierce) was 
used for dialysis. The membrane of the dialysis cassette was first hydrated for 2 
minutes in phosphate-buffered saline (PBS) and the FPLC-purified recombinant 
protein was carefully injected into the dialysis cassette. The dialysis cassette was then 
immersed in 1 litre of PBS with gentle stirring at 4°C with three changes of dialysis 
buffer with fresh PBS every 2 hours. Lastly, dialysis was performed overnight at 4°C 
and the recombinant protein was carefully withdrawn from the dialysis cassette. 
 
3.1.15 Concentration of protein by ultrafiltration 
The proteins were concentrated using Amicon® Ultra-15 Centrifugal Filter Device 
(Millipore). Protein sample was added to the Amicon Ultra-15 filter unit and 
centrifuged at 3,000 x g for 20 minutes. The filtrate was discarded and the 
concentrated protein recovered from the filter unit, and stored at -80°C. 
 
3.1.16 Quantitation of proteins by Bradford assay 
Bradford assay was performed using reagents from DC Protein Assay (Biorad). Serial 
dilutions of the protein standard BSA (1.6 mg/ml to 0.2 mg/ml) were prepared in PBS. 
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A ‘blank’ well (PBS) was also included. Five microlitres of standards and samples 
were added into the wells of a 96-well microplate and 25 μl of Reagent A was added 
into each well. The reaction of protein with copper in reagent A was detected with 
200 μl of Reagent B. After 15 minutes of colour development, absorbance was read at 
700 nm with Sunrise-Magellan ELISA reader (Tecan), with absorbance of ‘blank’ 
subtracted from each reading. The quantity of proteins was determined by comparing 
absorbance of the protein samples against the standard curve generated by BSA serial 
dilutions. 
 
3.1.17 Detection of endotoxin in recombinant proteins 
Endotoxin detection was performed with Limulus Amebocyte Lysate (LAL) QCL-
1000® kit (Cambrex). Prior to the assay, serial standard endotoxin concentrations (0.1 
to 1 EU/ml) were made in LAL Reagent water. Non-pyrogenic pipette tips, centrifuge 
tubes and other consumables were used. In the assay, 50 μl of protein samples, 
standards and ‘blank’ (LAL Reagent water) were added to the wells of pre-warmed 
96-well micoplate. Then, 50 μl of LAL were added to the wells for 10 minutes 
incubation at 37°C. The enzyme produced upon LAL reaction with endotoxin was 
detected adding 100 μl of substrate for 6 minutes incubation at 37°C. The reaction 
was stopped with 50 μl of stop reagent (10% SDS) added into each well. The 
absorbance was read at 410 nm with Sunrise-Magellan ELISA reader (Tecan) with 
‘blank’ reading subtracted from each well. Endotoxin concentrations in the samples 
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were calculated from the standard curve generated from the absorbance of the 
endotoxin standards. 
 
3.1.18 Endotoxin removal from recombinant proteins 
Endotrap Red kit (Lonza) was used for the removal of bacterial endotoxin from 
recombinant proteins, using an endotoxin-capture agarose bead column. The 
pre-packed column was first drained and washed with 6 column volumes of 
Regeneration Buffer, followed by rinsing with 6 column volumes of Equilibration 
Buffer. Protein sample was then applied to the column and sample was collected 
immediately. To elute the entire protein sample, 1 ml of Equilibration Buffer was 
added, the column was drained and all the eluate collected. The fractions were 
analysed by measuring absorbance at 280 nm to determine the presence of proteins in 
each fraction. 
 
3.2 Immunological study of human responses to mycobacterium antigens 
3.2.1 Study subjects 
Venous blood was collected from 66 anonymous healthy young adults (age 18 to 32) 
without specific known history of exposure to TB. All subjects had prior BCG 
vaccination at infancy and 90.9% (60 out of 66) of the study subjects had a further 
booster BCG vaccine at age 12 or 16. The study protocol was approved by the NUS 
Institutional Review Board for ethics of human studies. 
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3.2.2 Isolation of PBMCs 
RPMI 1640 medium (Sigma) supplemented with 2 mg/ml L-glutamine and 10% 
foetal calf serum (RPMI-10) was used for all the cell isolation and culture 
experiments. Within 6 hours of blood sample collection, PBMCs were isolated by 
density gradient centrifugation. Whole blood was diluted with RPMI-10, layered onto 
3 ml of Ficoll-Hypaque (Amersham Biosciences), and then centrifuged at 900 x g for 
18 minutes. The PBMC layer above the Ficoll was carefully extracted and platelets 
were further removed by centrifugation through an equal volume of foetal calf serum 
layered gradient. The cells were washed twice with RPMI-10 at 600 x g for 5 minutes, 
resuspended in an appropriate volume of RPMI-10 and viable cells counted by Trypan 
Blue exclusion method, with a haemocytometer. PBMCs were either used directly for 
antigen-stimulation or gradually cooled in an isopropanol bath (‘Mr Frosty’, Nalgene) 
and then transferred to liquid nitrogen storage until further use. 
 
3.2.3 Antigens used for PBMC stimulation and classification of subjects 
This assay to identify subjects with LTBI based on detection of PBMC responses to 
TB-specific proteins has been previously published (Arend et al. 2000). Ex-vivo 
PBMCs were stimulated with 20 μg/ml PPD (RT 50, Statens Serum Institute) or 
peptides of ESAT-6 and CFP-10 (10 μg/ml each, overlapping peptides spanning the 
full-length of each protein, synthesised by Invitrogen, sequences given in appendix 
section 7.8.1). PBS and phytohaemagglutinin (2 μg/ml) were used as negative and 
positive controls respectively. One million PBMCs were cultured in 200 μl RPMI-10 
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in 96-well round-bottom tissue culture plates for 5 days in 5% CO2 . The supernatants 
were collected for ELISA and the concentration of IFNγ four standard deviations (SD) 
above the mean concentration in unstimulated (PBS) wells was used as the cutoff 
level to detect antigen-responders. From this assay, three primary subject groups were 
initially defined. Those who responded to ESAT-6/CFP-10 peptides 
(ESAT-responders or ER) were considered to have LTBI. Those who did not respond 
to ESAT-6/CFP-10 peptides but were PPD-responders were classified as PPD+ENR 
(ESAT-nonresponders or ENR) and those who did not respond to either were 
classified as PPD-ENR. 
 
In a separate 96-well plate, 1.2 x 106 cells were stimulated with PPD at 10 μg/ml for 2 
days and supernatants were collected for assay of other cytokines. Cytokines assayed 
(IL6, IL10, IL12p40 and TNFα) are usually detectable within 18 to 72 hours with 
PPD stimulation (Hirsch et al. 1999; Lee et al. 2003), therefore a 2-day stimulation 
with PPD was chosen. 
 
A second panel of mycobacterium antigens was used to identify sub-groups within the 
study cohort. Selected peptides of PPE68 (Invitrogen, GL Biochem)(Brock et al. 2004) 
at 10 μg/ml of each peptide (sequences listed in appendix section 7.8.2), recombinant 
Ag85A (Lionex) at 20 μg/ml, recombinant Acr1 at 2.5 μg/ml, or recombinant Acr2 at 
10 μg/ml, were used to stimulate 2 x 105 viable PBMCs for 5 days as described above, 
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before supernatants were collected for IFNγ assay. PBS and phytohaemagglutinin 
were used as controls, as above. 
 
In a separate experiment, live M. bovis BCG was used to stimulate PBMCs for 
analysis of Tregs by flow cytometry. BCG was grown in Middlebrook 7H9 broth 
(Difco Laboratories), supplemented with 10% Middlebrook oleic acid, albumin, 
dextrose and catalase enrichment (OADC; Difco Laboratories) to optical density 
(OD600) of 0.4 to 0.8. The bacteria were centrifuged at 2500 x g for 10 minutes, 
washed in PBS and clumps removed by passing the bacteria suspension through a 
21G needle 4 to 6 times. Estimation of BCG numbers was performed based on OD600 
of 1 being approximately equivalent to 2.5 x 108 BCG/ml. One million PBMCs were 
incubated with live BCG at a multiplicity of infection of 10:1 in a total volume of 500 
μl in a 24-well tissue culture plate. Wells without BCG were included as controls. For 
the wells where BCG was added, ferric ammonium citrate (50 μg/ml, appendix 
section 7.9) was added for enhancing BCG survival. The cells were then incubated for 
4 days and the cells harvested for subsequent staining of surface markers or secreted 
cytokines. Joosten et al was able to detect CD8 Tregs upon stimulation of PBMCs 
from PPD responders on the 6th day of stimulation with live BCG (Joosten et al. 2007). 
By taking into consideration the massive amount of cell death at the end of 6 days of 
stimulation and the limited cell numbers from the study population, 4-day stimulation 




ELISA was performed with BD OptEIATM set (BD Biosciences) for detection of IFNγ, 
TNFα, IL6, IL10 and IL12p40, based on sandwich ELISA method. A 96-well flat 
bottom microplate with high binding surface (Costar) was coated with 100 μl of 
diluted capture antibody overnight at 4°C. The wells were aspirated and washed with 
Wash Buffer. The residual binding capacity of the plate was then blocked with 200 μl 
of Assay Diluent and incubated at room temperature for one hour. Wells were washed 
as above. Subsequently, 100 μl of sample or standards were added to the respective 
wells and incubated for 2 hours at room temperature. After washing, 100 μl of 
working detector (detection antibody mixed with avidin-horse radish peroxidase) was 
added and the plate incubated for 1 hour. Washing was repeated as above. For 
detection, 100 μl of substrate (tetramethylbenzidine and hydrogen peroxide) was 
added into each well for 30 minutes in the dark. Reaction was stopped by adding 50 
μl of Stop solution (1M H2SO4). The absorbance was taken at 450 nm with 
Sunrise-Magellan ELISA reader (Tecan). The detection limits for cytokine ELISA 
were 4.7 pg/ml for IFNγ and IL6, 7.8 pg/ml for TNFα and IL10 and 31.3 pg/ml for 
IL12p40. 
 
3.2.5 Flow cytometry: cell staining and antibodies used 
The fluorochrome-conjugated antibodies used were Alexa Fluor® 488 anti-CD4 
(clone RPA-T4; BioLegend), PE/Cy7 anti-CD25 (clone BC96; BioLegend), PE 
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anti-CD8 (clone RPA-T8; BioLegend), FITC anti-LAG-3 (clone 17B4; Alexis 
Biochemicals) and PE/Cy5 anti-CD107a (clone H4A3; BD Pharmingen). Isotype 
matched antibodies were used as controls (BioLegend, BD Pharmingen). 
 
For cell surface staining, 2 to 4 x 105 cells were washed in RPMI-10 and resuspended 
in 100 μl of Staining Buffer (0.5% BSA, 2mM EDTA in PBS). One to four 
microlitres of the appropriate antibodies were added for 30 minutes incubation at 4°C 
in the dark, followed by washing in 1 ml of Staining Buffer. Cells were centrifuged at 
600 x g for 5 minutes per wash. The cells were fixed with 100 μl of 4% 
paraformaldehyde. 
 
Cells secreting IFNγ and/or IL10 were detected with Cytokine Secretion Assay 
Detection kit (Miltenyi Biotec). The cells were first washed in 1 ml of Staining Buffer 
and centrifuged at 600 x g for 5 minutes, then resuspended in 80 μl of cold RPMI-10. 
The cells were incubated with 20 μl of premixed IFNγ and IL10 Catch Reagent on ice 
for 5 minutes. To allow cytokine secretion, the cells were incubated for 45 minutes in 
1 ml of warm RPMI-10 at 37°C with slow continuous rotation, then incubated on ice 
to inhibit cytokine secretion. After washing as above, the cells were resuspended in 80 
μl of Staining Buffer and stained with 20 μl of premixed IFNγ and IL10 detection 




Stained cells were stored at 4°C in the dark until analysis. CytomicsTM FC500 Flow 
Cytometer (Beckman Coulter) and CXP Analysis Software version 2.2 (Beckman 
Coulter) were used for cell acquisition and data analysis. 
 
3.2.6 RT-PCR 
One million fresh unstimulated PBMCs were stored at -80°C in TRIzol® Reagent 
(Invitrogen). RNA was extracted by first adding 0.2 ml of chloroform per 1 ml of 
TRIzol® to lysed cells and the upper aqueous phase containing RNA was transferred 
to a spin cup from Absolutely RNA® Miniprep Kit (Stratagene). RNA precipitation, 
binding to fiber matrix of RNA Binding Spin Cup, DNase treatment and elution were 
carried out according to manufacturer’s instructions. The concentration and purity of 
extracted RNA was determined from the absorbance at 260nm and A260/A280 
respectively, measured using Nanodrop ND-1000 spectrophotometer (Thermo 
Scientific). 
 
Reverse transcription of mRNA was performed as follows. First, 1 μl of oligo dT 
primer (Promega) which anneals to the polyA tail of mRNA was added to 20 ng of 
total RNA in a total reaction volume of 8 μl. First strand synthesis was performed at 
75°C for 5 minutes and was then cooled rapidly on ice. RT was performed in a 25 μl 
reaction using Promega reagents which includes 5 μl of Maloney Murine Leukemia 
Virus 5x reaction buffer, 5 μl of 10mM dNTP mix, 25 U RNasin ribonuclease 
inhibitor, 2.5 μl acetylated BSA (1 mg/ml), 200 U of Maloney Murine Leukemia 
 58
Virus reverse transcriptase, previous 8 μl of template and topped up with RNase free 
water. The reaction mixture was incubated at 42°C for 1 hour, followed by 95°C for 5 
minutes and the tubes placed on ice immediately. cDNA thus generated was stored at 
-20°C until PCR was performed. 
 
Cytokine cDNA from each subject was amplified using nested PCR, with their 
respective primers (appendix section 7.10). Amplification was performed in a 50 μl 
reaction using Promega reagents – 10 μl of 5x buffer, 3 μl of 25mM MgCl2, 2 μl of 
10mM dNTP, 1 μl of 10μΜ stock of forward and reverse primer, 0.25 μl of GoTaq 
polymerase and 1 μl of cDNA template. The PCR reaction conditions are listed in the 
appendix section 7.11. 
 
3.2.7 cRNA standards and optimisation of PCR conditions 
For accurate quantification of cytokine RNA, it is important to ensure that the original 
RNA copy number in each sample is reflected in the final PCR amplicon quantity. As 
a quality control for every RT-PCR reaction, a set of cRNA standards for each 
cytokine studied was generated as follows. First, for each cytokine gene, modified 
PCR amplicons bearing the T7 RNA polymerase promoter site at the 5’ end and a 
poly d(T) sequence at the 3’ end were generated, by modifying the PCR primers with 
the respective additional sites (Seah and Rook 1999). These primers were termed the 
T7-dT modified primers (appendix section 7.10). These modified amplicons for each 
cytokine gene were analysed by agarose gel electrophoresis and purified with PCR 
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product purification kit (Qiagen). They were used as templates for in vitro 
transcription with the Ribroprobe T7 in vitro transcription system (Promega). Each 
transcription reaction consisted of 20 μl of transcription optimised 5x buffer, 10 μl of 
100mM dithiothreitol, 100 U of recombinant RNasin ribonuclease inhibitor, 20 μl of 
2.5mM each of rATP, rGTP. rCTP and rUTP, 1.0 to 2.5 mg/ml of linearised cDNA 
template and 40 U of T7 RNA polymerase. The mixture was incubated for 1 hour at 
37°C. Subsequently, excess cDNA was removed by DNase treatment and cRNA 
extracted and purified according to manufacturer’s instructions. cRNA purity and 
concentration (pmol/μl) were determined. The cRNA for each cytokine gene was 
adjusted to desired concentration per microliter (e.g. 1012). A set of cRNA standards 
was obtained by 10-fold serial dilutions in RNAse-free water. Each set of standards 
was used for RT-PCR in parallel with sample RNA extracted from PBMCs of each 
study subject. 
 
Reaction condition optimisation was performed with the cDNA that was reverse 
transcribed from each set of cytokine cRNA standards, to ensure that within a given 
range of standards, at the chosen PCR amplification conditions, there was a linear 
relationship between log cytokine RNA copy number and log final fluorescence 
intensity of the PCR amplicons. Nested PCR was performed, with first and second 
round PCR amplification conducted respectively with pairs of outer and inner primers 
(appendix section 7.10). For the second round PCR, PCR master mix was made in a 
fresh tube as above while 1 μl of first round PCR product was used as the DNA 
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template. PCR conditions for first and second round PCR reactions are listed in 
appendix section 7.11. 
 
3.2.8 Quantifying RNA in samples 
The PCR amplicons obtained for each cytokine gene were visualised following 
electrophoresis in 1.3% agarose gels, cast with 0.5 μg/ml ethidium bromide. The PCR 
amplicons from the relevant set of standards were always included in the same gel. 
The gels were first assessed for presence of specific bands of correct molecular 
weight upon scanning on a fluorescence image analyser (Typhoon 9200, Amersham). 
The band intensities were subsequently analysed with Science Lab 97 Image Gauge 
Version 3.01 software (Fuji Photo Film), in relation to a standard curve relating the 
log fluorescence intensities of bands produced by the cRNA standards, and the log 
cRNA copy number. The standard curve was rejected if the points did not fall within a 
straight line (R<0.96). Quantification of cytokine mRNA in each subject’s sample 
was done by reading off RNA copy number from this linear cRNA standard curve. 
The number of copies of cytokine RNA samples per microgram of total RNA was 
calculated for normalisation between samples. 
 
3.2.9 Statistics 
Mann Whitney U test (non-parametric) was used to compute statistical significance of 
comparisons between group medians using MINITAB® (version 14.1) software. The 
 61
association between two parameters was determined with the chi-square test and 
correlation between two parameters was performed using Spearman rank correlation, 
with software SPSS 15.0. A p value of less than 0.05 was considered significant. 
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CHAPTER 4 RESULTS 
4.1 Recombinant protein production 
4.1.1 Optimisation of induction time for maximal expression 
After plasmid construction and sequencing to verify that the cloned genes (acr1 and 
acr2) were identical with the published genome sequence, the E. coli expression strain 
was transformed and protein expression tested at 2, 4 and 6 hours after IPTG addition, 
to find the optimal induction time. Using Compute pI/MW tool in ExPASy server, 
predicted molecular weights of Acr1 and Acr2 were 19 and 21 kDa respectively. 
Protein bands of the predicted sizes for both Acr1 and Acr2 were expressed at similar 
high levels at the three time points (Fig 3). Therefore, a 2 hour induction with 2mM 
IPTG was chosen for the expression of these proteins. 
 
Figure 3. Western blot of E.coli cell lysates with differential IPTG induction. E. coli with 
pET-11a vector expressing Acr1 or Acr2 were grown overnight in 200 ml LB/ampicillin broth 
until OD600 reached 0.4 to 0.8, after which the culture was induced with 2mM IPTG for 2, 4 
or 6 hours. Cells were harvested at the various time-points post-induction, lysed and 











Figure 4. Protein purification chromatograms. (A) Chromatogram showing the peak (thick arrow) containing eluted Acr1 protein during FPLC. Inset: 
Coomassie staining of proteins in the different fractions upon elution. WT: washthrough FT: flowthrough. E.coli cell lysate with Acr1 protein expressed were 
put through a nickel column which binds His-tagged recombinant Acr1 protein. The bound recombinant proteins were washed and eluted with increasing 
concentrations of imidazole 
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Figure 4. (B) Chromatogram showing the peak (thick arrow) containing eluted Acr2 protein during FPLC. Inset: Coomassie staining of proteins in the 
different fractions upon elution. WT: washthrough FT: flowthrough. E.coli cell lysate with Acr2 protein expressed were put through a nickel column which 
binds His-tagged recombinant Acr2 protein. The bound recombinant proteins were washed and eluted with increasing concentrations of imidazole 
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4.1.2 Purification of His-tagged recombinant proteins 
Acr1 and Acr2 were expressed and purified by FPLC through a nickel column. The 
chromatogram and Coomassie staining of fractions shows that Acr1 (Fig 4A) and 
Acr2 (Fig 4B) proteins were obtained from the soluble fraction of cell lysate, while 
other contaminating proteins present in cell lysate were removed in the ‘washthrough’ 
eluate. Following purification, dialysis to remove imidazole used for elution and 
endotoxin removal, the final recombinant proteins to be used in further experiments 
were visualised on SDS-PAGE gel and Western blot confirming the molecular 
weights and purity (Fig 5A, B). 
 
Figure 5. Verification of purified proteins. (A) Western Blot using anti-His and (B) 
Coomassie staining of the final purified Acr1 and Acr2 protein used for further experiments. 
OVA= ovalbumin. OVA was used as a negative control to confirm the specificity of anti-His 
antibody detection of His-tagged proteins. Predicted sizes of recombinant Acr1 and Acr2 are 
19 kDa and 21 kDa respectively. 
 66
4.1.3 Mass spectrometry analysis of proteins 
The recombinant protein bands were excised, digested and analysed by mass 
spectrometry. The peptide mass fingerprints obtained for Acr1 and Acr2 (Fig 6A, B) 
were searched against a list of theoretically predicted peptide mass fingerprints in a 
protein database using MASCOT search tool. The top Probability Based Mowse 
Score for Acr1 observed peptide mass fingerprint corresponded to HspX or Acr1 in 
Mtb (score 231) while the second highest corresponded to “19 kDa major membrane 
protein in M. tuberculosis” (score 222). By comparing protein sequences of these two 
proteins with the top scores, it was found that the two proteins were 100% identical 
and thus they were the same protein. For the peptide mass fingerprint of putative Acr2 
protein, the top Probability Based Mowse Score was 460 and this corresponded to 
heat shock protein of HSP20 family of Mtb. This protein sequence was 100% 
identical to Acr2 protein. Some random peptide fragments were very weakly matched 
to non-Acr proteins but with very low scores relative to the Acr protein match. 
Therefore, identities of the recombinant proteins generated were confirmed as the 
desired Acr1 and Acr2 of Mtb. 
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Figure 6. Peptide mass analysis by mass spectrometry. (A) Mass spectrometry analysis of peptide masses of recombinant Acr1. Black arrows indicate matches 
to theoretically predicted peptides for Acr1 protein. 
 
 68 
Figure 6. (B) Mass spectrometry analysis of peptide masses of recombinant Acr2. Black arrows indicate matches to theoretically predicted peptides for Acr2 
protein.
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4.2 IFNγ responses to mycobacterial antigens in ER, PPD+ENR, PPD-ENR 
groups 
We first classified our study cohort of young clinically healthy adults without specific 
history of TB exposure or disease, into three categories – those with no memory 
responses to any mycobacterial antigens, those with memory responses to BCG vaccine 
and/or environmental mycobacteria, and those with LTBI acquired through unknowing 
exposure to an active TB case in Singapore, where there is moderate TB endemicity. 
There is no gold standard for LTBI diagnosis, but based on abundant evidence that 
responses to ESAT-6/CFP-10 identify healthy people with LTBI, we first classified 
ESAT-6/CFP-10-responders (ER) as those with probable LTBI. Amongst 
ESAT-6/CFP-10-nonresponders (ENR), i.e. those who are less likely to have LTBI, those 
with positive PPD responses were regarded as subjects with some prior mycobacterium 
exposure, because PPD contains multiple cross-reacting antigens shared widely within 
the Mycobacterium genus (including with M. bovis BCG or environmental mycobacteria). 
Thus, the PPD-negative ENR group was assumed to represent subjects without any 
memory responses to BCG or environmental mycobacteria, i.e. mycobacterium-naïve 
(negative control group). The numbers of subjects in each of the three groups are 
indicated in Table 1. We investigated responses of these three groups to antigens PPD, 
PPE68, Ag85A, Acr1 and Acr2 by assaying the IFNγ response in supernatants. 
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4.2.1 Magnitude of mycobacterium antigen responses 
ER and PPD+ENR were comparable in their responses to PPE68 and Ag85A, but both 
were significantly higher than the PPD-ENR group (Fig 7A, B). ER and PPD+ENR also 
had slightly higher responses to Acr1 and Acr2, though these differences were not 
significantly different from the mycobacterium-naïve group (Fig 7C, D). 
 
 
Figure 7. Magnitude of IFNγ production in response to mycobacterium antigens. PBMCs from 
subjects in different groups were stimulated for five days with antigens as indicated, and ELISA 
used to assay IFNγ production. Group medians indicated, statistics by Mann Whitney U test. 
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4.2.2 Antigen-specific response rates and associations with responses to other 
antigens 
The same trend was also reflected in the percentage of positive responders towards the 
various mycobacterial antigens (Table 1A). PPE68, an RD1 protein, is an Mtb-specific 
antigen suggested as an additional or alternative marker for LTBI (Brock et al. 2004), to 
complement ESAT-6 and CFP-10. Only 37.9% of ER responded to PPE68 and a similar 
proportion (45.8%) of PPD+ENR responded to PPE68 (Table 1A, B). Thus, in our cohort, 
the concordance between these different latency markers was quite low, and the ER 
(LTBI) and ENR subjects could not be distinguished by their PPE68 responses. Ag85A 
responders were anticipated to include those with LTBI as well as those exposed to BCG 
vaccine or other environmental mycobacteria (PPD responders) since this immunogenic 
protein is expressed by many mycobacterium species (Wiker and Harboe 1992). However, 
only 29.2% of ER responded to Ag85A (Table 1A), but out of all Ag85A responders, 
63.6% responded to ESAT-6/CFP-10 (Table 1B). There was also a low percentage of 
Ag85A responders (21.1%) observed in the PPD+ENR group even though Ag85 is a 
component of PPD (Table 1A). A very high proportion (90.9%) of Ag85A responders 
reacted to PPE68 (Table 1B), but only 50% of PPE68 responders reacted to Ag85A. Less 
than half of the ESAT-6/CFP-10 responders or the PPE68 responders reacted to Acr1 or 2 
(Table 1B). Comparable proportions (16 – 22%) of Acr1 responders were seen in all 
groups (Table 1A), but percentage of Acr2 responders amongst ER (37.5%) was clearly 
higher than PPD+ENR (25%) and PPD-ENR (20%) groups (Table 1A). Just over half of 





Table 1. Response rates to mycobacterium antigens. Criteria for defining positive responses are 
given in Methods. (A) Percentage (and actual numbers) within each group showing positive 
responses towards five mycobacterial antigens. (B) Subjects with positive responses to each 
antigen are shown in left column. Table shows percentage of those antigen responders who have 
concomitantly positive responses towards the other mycobacterial antigens listed in the 
subsequent columns. 
 
The main significant associations between responses to the four mycobacterial antigens 
were found to be between PPE68 and Ag85A, and between Acr1 and Acr2 (Table 2A). 
The association between PPE68 and Ag85A was only seen in ER and PPD+ENR groups 
(Table 2B, C) and the link between Acr1 and Acr2 was mainly in the ER group only 
(Table 2B). Amongst the ER (Fig 8), there was a correlation between Ag85A and PPE68, 
as well as between Acr1 and Acr2. This correlation was not consistently seen in the other 
two groups, supporting the notion that it is mainly in LTBI subjects where there is 




Table 2. Associations between responses towards various mycobacterial antigens in (A) total 
subjects (B) ER (C) PPD+ENR and (D) PPD-ENR groups. Criteria for defining positive 
responses to each antigen are given in Methods. Associations were determined by the chi-square 
test. p values are shown in the table. Significant p values are marked with an asterisk. NA: not 




Figure 8. ESAT-6/CFP-10 responders show correlation between key immunodominant antigens 
and latency antigens. Specific IFNγ responses to mycobacterium antigens (A) PPE68 and Ag85A, 
and (B) Acr1 and Acr2 for each individual in the ER group is shown. Correlations by Spearman 
rank sum correlation, regression line shown. 
 
4.3 Cytokine profiles of ER, PPD+ENR and PPD-ENR 
We hypothesised that the pro-inflammatory and regulatory cytokine production in 
response to PPD could be linked to the levels of mycobacterium-specific memory 
responses. In all three groups, PPD-stimulated PBMCs produced comparable levels of the 
predominantly monocyte/macrophage cytokines (IL6, IL10, IL12 and TNFα) (Fig 9A). 
Unstimulated PBMC cytokine mRNA levels for pro-inflammatory and Th1 related 
cytokines IL6, IFNγ, IL12p35 and IL18 as well as Treg related cytokine TGFβ and 
transcription factor FoxP3 were also similar between the three groups. The notable 
exception was in the expression levels of IL10 and IL4 (Fig 9B). ER and PPD+ENR had 
significantly higher IL10 mRNA expression than PPD-ENR group. PPD+ENR group 
which had the highest IL10 mRNA expression also had the lowest IL4 mRNA levels 
(Fig 9B). In the ER subjects, but not in either of the ENR groups, IL10 was positively 
correlated with IL4 (Fig 10). 
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Figure 9. Cytokine profiles of ER, PPD+ENR and PPD-ENR groups. (A) Cytokine production in 
supernatants by ELISA after 2 day PBMC stimulation with PPD. (B) Basal cytokine mRNA 
expression in unstimulated PBMCs assessed by RT-PCR. Mann Whitney U test was used to 





Figure 10. Correlation between basal IL10 and IL4 mRNA expression levels. (A) ER (n=31) (B) 
PPD+ENR (n= 21) and (C) PPD-ENR (n = 9) groups are shown. Statistics by Spearman rank sum 
correlation, regression lines shown. 
 
4.4 Correlations between different cytokines in LTBI subjects 
4.4.1 Regulatory cytokines and pro-inflammatory cytokines 
We hypothesised that in the presence of latent mycobacteria persistently stimulating host 
immunity, there would be inflammatory cytokines induced, which in turn may induce 
regulatory cytokine production. Thus, the correlation between regulatory cytokines IL10 
and TGFβ, and pro-inflammatory cytokines IL6, TNFα and IFNγ was investigated in the 
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ER group. The PPD-specific IL10 production levels were positively correlated with IL6 
and TNFα production in ER (Fig 11A, B) and ENR but not correlated with 
IFNγ production (data not shown). A positive correlation between PPD-stimulated IL6 
and TNFα production (Fig 12A), as well as between TNFα and IFNγ production was 
observed in ER (Fig 12B) as well as in ENR (data not shown).  
 
 
Figure 11. Correlation between PPD-specific IL10 levels with pro-inflammatory cytokines (IL6 





Figure 12. Correlation between PPD-specific pro-inflammatory cytokine responses in ER group 
(n=32). Statistics by Spearman rank correlation, regression lines shown. 
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4.4.2 Regulatory cytokines and Th1 related cytokines 
Correlations between regulatory cytokines and Th1 related cytokines IL12, IL18 and 
IFNγ were investigated in the three groups. IL18 mRNA expression was positively 
correlated with unstimulated IL10 expression but negatively correlated with 
TGFβ mRNA expression in the ER group (Fig 13A, B). IL12p35, on the other hand, was 
positively correlated with TGFβ in the ER group (Fig 13C) but not in the ENR group 
(data not shown). A negative correlation was seen between IL10 and TGFβ mRNA 
expression only in the ER group (Fig 14). Thus it appears that either IL10 and TGFβ, but 
not both simultaneously, may be involved in the regulatory response in LTBI. 
 
It is known that a principal cytokine induced and central to cell-mediated immunity 
against TB is IFNγ, and cytokines IL12 and IL18 have been implicated in induction of 
IFNγ production (Okamura et al. 1998). Thus, it was of interest to discover if IL18 or 
IL12 expression correlated with IFNγ expression in latently infected people (ER) who 
should be producing IFNγ responses to the persistent mycobacteria. First, it was noted 
that IL12p35 and IL18 mRNA expression levels were not correlated in the ER group 
(data not shown). IL12p35 expression was positively correlated with IFNγ expression in 
ER (Fig 15A) but not in the ENR group, while IL18 expression was not correlated, with 
IFNγ expression (Fig 15B). Thus, IL12 is more likely to be the inducer of IFNγ 




Figure 13. Correlation between Th1-related cytokines and regulatory cytokines in ER group 
(n=32).  (A) IL18 vs IL10 (B) IL18 vs TGFβ (C) TGFβ vs IL12p35. mRNA expression shown as 




Figure 14. Correlation between regulatory cytokines IL10 and TGFβ unstimulated mRNA 
expression in ER group (n = 32). mRNA expression shown as copy number per microgram total 




Figure 15. Positive and negative correlations between unstimulated IFNγ, IL12p35 and IL18 
mRNA expression in ER group (n=32). mRNA expression shown as copy number per microgram 
total RNA. Statistics by Spearman rank sum correlation, regression lines shown. 
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4.4.3 Th1 and Th2 cytokines 
It has been suggested that there are elevated Th2 responses in patients with active TB 
(Seah et al. 2000; Hussain et al. 2002; Lee et al. 2003; Dheda et al. 2005), and some 
mechanisms have been proposed on how this may subvert the host immunity against 
mycobacteria (VanHeyningen et al. 1997; Nagabhushanam et al. 2003; Kahnert et al. 
2006). We thus looked at the correlations between expression of cytokines related to Th1 
responses and those related to Th2 responses in subjects with LTBI (ER). IFNγ and IL4 
mRNA expression were negatively correlated in the ER group (Fig 16A) but not in the 
ENR group (data not shown). However, expression of the Th2 cytokine IL4 was 
positively correlated with IL18 in both ER (Fig 16B) and ENR groups (data not shown). 
 
 
Figure 16. Negative and positive correlations between expression of IL4 and Th1 cytokines (A) 
IFNγ and (B) IL18 in unstimulated cells of ER group subjects (n=31). mRNA expression shown 
as copy number per microgram total RNA. Statistics by Spearman rank sum correlation, 
regression lines shown. 
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4.5 T regulatory cells and associated cytokines in ER, PPD+ENR and PPD-
ENR groups 
4.5.1 CD8 Tregs and associated cytokines 
Joosten and coworkers recently identified a CD8 Treg subset, seen upon restimulation of 
PBMCs from healthy PPD responders with live BCG (Joosten et al. 2007). This CD8 
Treg subset expresses LAG3 and majority of such cells express CD25. CD8+CD25+ cells 
also express other Treg markers such as cytotoxic T lymphocyte antigen 4 and FoxP3, 
and the CD8+LAG3+ cells have suppressive activity (Joosten et al. 2007). However, the 
authors did not distinguish between LTBI and ENR subjects in their study. 
 
In order to determine whether there was differential mycobacterium-specific CD8 Treg 
induction in our three subject groups, PBMCs stimulated with live BCG for 4 days were 
analysed by flow cytometry. ER and PPD+ENR had significantly higher proportions of 
CD8+CD25+ and CD8+LAG3+ cells compared with PPD-ENR (Fig 17). With respect to 
CD8+CD25+ cells, PPD+ENR had the highest percentage of such cells. ER had a 
significantly lower percentage than PPD+ENR but significantly higher than PPD-ENR. A 
similar trend was seen for CD8+LAG3+ cells (Fig 17), supporting Joosten’s observations 
that the two cell populations are linked. 
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Figure 17. Percentage of CD8+CD25+ and CD8+LAG3+ cells in ER, PPD+ENR and PPD-ENR 
groups. PBMCs were stimulated with live BCG for 4 days, after which cells were washed, stained 
and analysed by flow cytometry, gated on lymphocytes. Mann Whitney U test was used to 
compare differences between groups. Group medians are shown, error bars indicate 25th and 75th 
percentiles. 
 
In the groups showing higher proportions of CD8 Tregs, we were interested to know if 
presence of these cells was correlated with regulatory cytokines IL10 and TGFβ, 
previously known to be associated with Tregs in a different context (Boussiotis et al. 
2000; Bluestone and Abbas 2003). Due to the limited availability of cells, only 
CD8+CD25+ cells were analysed. The proportion of CD8+CD25+ cells for each subject 
was not correlated with expression of IL10 and TGFβ mRNA in the same subject, in ER 
and PPD+ENR groups (Fig 18A, B), therefore CD8+CD25+ cells are unlikely to be 
associated with these cytokines. However, the percentage of CD8+CD25+ cells and FoxP3 
mRNA expression were significantly correlated in the ER group, but not in PPD+ENR 
group (Fig 18C), supporting the possibility that in LTBI, CD8+CD25+ cells may be the 
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source of FoxP3. We acknowledge that the limitation of these correlations is that 
phenotyping and mRNA expression studies were performed on different aliquots of cells 
from the same subjects. We were not able to perform direct intracellular staining of the 
CD8 Tregs due to the limited cell numbers available for each subject. 
 
We hypothesised that presence of CD8 Tregs may be linked to on-going inflammatory 
responses in the subjects. Thus, the correlations between percentages of CD8+CD25+ 
cells and level of PPD-specific cytokines were studied in the three groups. There was 
significant positive correlation of CD8+CD25+ cells with pro-inflammatory cytokines IL6 
and TNFα in PPD+ENR, but this correlation was not observed in ER subjects (Fig 19A, 
B). Therefore, the evidence does not suggest that in LTBI, the CD8 Tregs are responding 




Figure 18. Correlation studies of percentage of CD8+CD25+ cells and unstimulated cytokine 
expression in ER (n = 21) and PPD+ENR (n=17) groups. PBMCs were stimulated with live BCG 
for 4 days, after which cells were washed, stained and analysed for Treg markers by flow 
cytometry, gated on lymphocytes. mRNA expression shown as copy number per microgram total 
RNA. Since not all subjects had detectable FoxP3 mRNA levels, fewer subjects were analysed for 




Figure 19. Correlations between percentages of CD8 Tregs and PPD-specific pro-inflammatory 
cytokine production in ER (n= 21) and PPD+ENR (n=17) groups. PBMCs were stimulated with 
live BCG for 4 days, after which cells were washed, stained and analysed for Treg markers by 
flow cytometry, gated on lymphocytes. Cytokine levels were measured by ELISA after 2-day 
PPD stimulation. Statistics by Spearman rank sum correlation, regression lines shown. 
 
4.5.2 Natural CD4 Tregs and associated cytokines 
Natural CD4 Tregs, characterised by CD4+CD25+ phenotype (Bluestone and Abbas 2003; 
Mills 2004), were analysed after live BCG stimulation of PBMCs for 4 days ex vivo. The 
percentages of CD4+CD25+ cells were slightly higher in ER and PPD+ENR, than 
PPD-ENR, though this was not statistically significant (Fig 20). No differences were 
observed in the percentages of CD4+IFNγ+ and CD4+IL10+ cells in the 3 groups (Fig 20). 
Since CD4+CD25+ cells are known to be able to produce regulatory cytokines to inhibit 
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proliferation of immune cells, we looked for correlations between CD4+CD25+ cells and 
the total mRNA level of regulatory cytokines, which may support a possibility that they 
could be produced by CD4+CD25+ cells. Similar to CD8+CD25+ cells, the percentage of 
CD4+CD25+ cells was also not correlated with IL10 or TGFβ expression in unstimulated 
PBMCs of either ER or PPD+ENR subjects (data not shown). However, the percentage 
of CD4+CD25+ cells was negatively correlated with pro-inflammatory cytokines IL6 and 
TNFα, as well as expression of Th2 cytokine IL4 in ER (Fig 21) but not in PPD+ENR 
subjects (data not shown). 
 
Figure 20. Percentage of CD4+CD25+, CD4+IFNγ+ and CD4+IL10+ cells in ER, PPD+ENR and 
PPD-ENR groups. PBMCs were stimulated with live BCG for 4 days, after which cells were 
washed, stained and analysed by flow cytometry, gated on lymphocytes. Statistical comparison of 
different groups was performed by Mann Whitney U test. Group medians are shown, error bars 




Figure 21. Correlation study of CD4 Tregs and cytokine expression in ER (n=7). PBMCs were 
stimulated with live BCG for 4 days, after which cells were washed, stained and analysed for 
Treg markers by flow cytometry, gated on lymphocytes. mRNA expression in unstimulated cells 
shown as copy number per microgram total RNA. Statistics by Spearman rank correlation, 
regression lines shown. 
 
It was of interest to know whether CD4 and CD8 Tregs are concurrently elevated in the 
same subject, since the stimuli for their production may be different. A subset of subjects 
for whom CD8 Treg analysis was done was analysed for expression of CD4 Treg markers 
The limited group size did not permit us to meaningfully analyse ER and ENR groups 
separately, thus these groups were combined to represent the whole healthy cohort. 
Overall, the percentages of CD4+CD25+ cells and CD8+CD25+ cells were positively 
correlated (Fig 22A). Additionally, in contrast to the outcome for ER or PPD+ENR alone 
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(Fig. 18A) percentage of CD8+CD25+ cells was positively correlated with basal IL10 
mRNA levels in this analysis of all subjects (Fig 22B), but percentage of CD4+CD25+ 
cells was not correlated with IL10 expression (Fig 22C). Neither CD8+CD25+ nor 
CD4+CD25+ cell percentages was correlated with TGFβ mRNA levels (data not shown). 
 
 
Figure 22. Correlations between CD4 and CD8 Tregs, and unstimulated IL10 mRNA expression 
in all study subjects tested. Due to cell number limitations, CD8 Treg markers were studied in 46 
subjects (21 ER, 25 ENR) and of these, 16 subjects (7 ER, 9 ENR) had CD4 Treg markers 
assessed as well. PBMCs were stimulated with live BCG for 4 days, after which cells were 
washed, stained and analysed by flow cytometry, gated on lymphocytes. mRNA expression in 
unstimulated cells shown as copy number per microgram total RNA. Statistics by Spearman rank 
sum correlation, regression lines shown. 
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4.6 Immune responses in healthy subjects with recent and remote acquisition 
of LTBI 
4.6.1 IFNγ responses to mycobacterial antigens 
Latently infected people may have recent or remote exposure to Mtb, and it is possible 
that these two groups have different immune responses. Responses to Acr2 have been 
associated with recent contact with Mtb (Wilkinson et al. 2005). If those LTBI subjects 
with recent exposure are defined as Acr2 responders, we hypothesised that these (Acr2+) 
people could have higher Mtb-induced pro-inflammatory and regulatory cytokine 
expression, relative to LTBI subjects with remote Mtb exposure. 
 
Like ESAT-6/CFP-10, PPE68 is encoded in the RD1 region of the Mtb genome, and 
therefore, is expected to be an Mtb-specific antigen too. From data in Table 1, it is 
evident that not all ERs responded to PPE68. Conversely, some of the ENR group 
responded to PPE68 – these could be LTBI subjects who were undetected based on the 
ESAT-6/CFP-10 response alone. Therefore, in the next part of the analysis, we looked at 
subjects with either ESAT/CFP+ or PPE68+ responses as potential LTBI subjects (‘TB 
exposed’). Those who were LTBI by this definition and additionally Acr2+ were 
regarded as ‘recently exposed LTBI’, while those who were either ESAT/CFP+ or 
PPE68+ but Acr2- were regarded as ‘remotely exposed LTBI’ subjects. We regarded 
those who were negative for all antigens (i.e. ESAT/CFP-PPE68-Ag85A-Acr2-) as 
people who were not exposed to Mtb (‘TB unexposed’). We looked for differential 
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cytokine and Treg responses in recently versus remotely exposed subjects and compared 
these with the TB unexposed group. 
 
Figure 23. Acr1 response in recently exposed, remotely exposed and TB unexposed groups. IFNγ 
production following 5-day stimulation of PBMCs with Acr1 was determined by ELISA. Group 
medians (horizontal bars) were compared using the Mann Whitney U test. Recently exposed 
persons defined as either ESAT/CFP+ or PPE68+, and Acr2+ Remotely exposed persons defined 
as either ESAT/CFP+ or PPE68+, and Acr2-. TB unexposed persons defined as ESAT/CFP-
PPE68-Ag85A-Acr2- . 
 
The recently exposed group (Acr2+) had significantly higher IFNγ responses to Acr1, 
relative to remotely exposed and TB unexposed groups (Fig 23). Reactivity to 
ESAT/CFP was significantly associated with reactivity to PPE68 in both recently and 
remotely exposed groups (Table 3). However, there were no significant correlations 
between the magnitudes of ESAT/CFP and PPE68 responses (data not shown). PPE68 
responses were significantly correlated with Ag85A responses for all 3 groups, with the 
highest correlation coefficient in the recently exposed group, followed by remotely 
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exposed group, and the lowest correlation coefficient in the TB unexposed group (Fig 24). 
This immune reactivity pattern to Mtb antigens is biologically consistent with our 
classification of the recently and remotely exposed LTBI subjects. 
 
 
Table 3. Associations between mycobacterial antigen responses in (A) recently exposed and (B) 
remotely exposed groups. Five-day stimulated PBMC responses to the different antigens 
indicated were assayed by ELISA and criteria for positive responses to each antigen are defined 
in Methods. Associations were measured using chi-square test. p values are shown in the table, 




Figure 24. Correlation between IFNγ responses to mycobacterium antigens Ag85A and PPE68 
based on TB exposure status. (A) recently exposed (n=13), (B) remotely exposed (n= 20) and (C) 
TB unexposed (n=14) groups were studied. Statistics by Spearman rank sum correlation, 
regression lines shown. 
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4.6.2 Cytokine profiles 
The recently, remotely exposed and TB unexposed groups had comparable levels of IL6, 
IL10, IL12p40 and TNFα production, after 2 days of PPD stimulation (Fig 25A). As for 
unstimulated cytokine mRNA expression, the recently exposed LTBI group had the 
highest IL12p35 and IFNγ mRNA expression levels, which were significantly higher than 
the remotely exposed group (Fig 25B). This agrees with the likelihood that recently 
exposed subjects mount stronger Th1 responses against the latent Mtb, and again lends 
support to the biological consistency of using the Acr2 response to define the remoteness 
of exposure. IL10 mRNA expression was the lowest in PPD- TB unexposed group, 
significantly lower than both TB exposed groups and PPD+ TB unexposed group. No 
significant differences were seen between the 4 groups for the other cytokines studied 
(Fig 25B). 
 
Since recently exposed subjects had highest IL12p35 and IFNγ mRNA levels, and it is 
known that IL12 induces polarisation of Th1 cells (O'Garra 1998; Glimcher and Murphy 
2000), we examined whether IL12p35 expression levels were correlated with IFNγ 
mRNA expression in this group. We found that indeed, IL12p35 mRNA expression was 
positively correlated with IFNγ mRNA expression in recently exposed but not remotely 
exposed individuals with LTBI (Fig 26). 
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Figure 25. Cytokine profiles of recently exposed, remotely exposed LTBI groups, in comparison 
with PPD+ and PPD- TB unexposed groups. (A) Cytokine production following 2-day 
stimulation with PPD was determined by ELISA. (B) Basal cytokine mRNA expression in 
unstimulated PBMCs assessed by RT-PCR. Group medians shown, statistical differences between 





Figure 26. Correlation between basal IFNγ and IL12p35 mRNA expression in recently exposed 
and remotely exposed LTBI subjects. Subjects with either ESAT/CFP+ or PPE68+ responses 
were regarded as potential LTBI subjects (‘TB exposed’). Amongst these, Acr2+ subjects were 
regarded as recently exposed (n=15) and Acr2- subjects as remotely exposed (n=27). mRNA 
expression in unstimulated cells shown as copy number per microgram total RNA. Statistics by 
Spearman rank sum correlation, regression lines shown. 
 
4.6.3 CD8 Tregs  
The PPD- TB unexposed group had the lowest percentage of CD8+CD25+ cells while 
both PPD+ TB unexposed and recently exposed had the highest percentages (Fig 27). The 
CD8+LAG3+ cells showed a similar trend, though no significant differences were 
observed between groups (Fig 27). In recently exposed subjects, the group with the 
highest levels of IFNγ expression, the percentage of CD8+CD25+ cells was not correlated 
with either IL12p35 or IFNγ mRNA expression (data not shown). The percentage of 
CD8+CD25+ cells was also not correlated with regulatory cytokines IL10 and TGFβ 
mRNA expression in either recently or remotely exposed subjects (data not shown). 
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Figure 27. Percentage of CD8+CD25+ and CD8+LAG3+ cells in recently exposed and remotely 
exposed LTBI subjects, in comparison with PPD+ and PPD- TB unexposed groups. PBMCs were 
stimulated with live BCG for 4 days, after which cells were washed, stained and analysed for 
Treg markers by flow cytometry, gated on lymphocytes. Group medians shown, error bars 
indicate 25th and 75th percentiles. Statistics by Mann Whitney U test.  
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4.7 New subgroups based on differential reactivity to various 
mycobacterium antigens 
4.7.1 Cytokine profiles of Ag85A+Acr2+ LTBI and Ag85A-Acr2- LTBI subjects 
We postulated that amongst those with possible LTBI (ESAT/CFP+ or PPE68+), subjects 
who responded to all mycobacterial antigens tested (i.e. Ag85A+Acr2+) may have 
stronger cytokine and Treg responses than those who were Ag85A-Acr2-. The cytokine 
profiles of these two groups were investigated. However, there was generally little 
difference in cytokine production after 2 day stimulation with PPD (Fig 28A). There were 
also no significant differences between the two groups in basal mRNA expression levels 
of the cytokines studied (Fig 28B). Therefore, there was no evidence to support the use of 
the Ag85A+Acr2+ profile to identify those LTBI subjects with a stronger antigen load. 
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Figure 28. Cytokine profiles of Ag85A+Acr2+ LTBI and Ag85A-Acr2- LTBI subjects. Subjects 
responding to either ESAT/CFP or PPE68 or both were studied as potential LTBI subjects in this 
analysis. (A) Cytokine production assessed by ELISA after 2 day PPD stimulation of PBMCs. (B) 
Basal cytokine mRNA expression in unstimulated PBMCs assessed by RT-PCR. Statistics by 
Mann Whitney U test, group medians are shown, error bars indicate 25th and 75th percentiles. 
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4.7.2 Reactivity to RD1 antigens: Comparing ESAT+PPE68+, ESAT+PPE68-, 
ESAT-PPE68+ and ESAT-PPE68- groups 
It has previously been discussed that as ESAT-6/CFP-10 and PPE68 peptides do not have 
100% sensitivity in the detection of latently infected people, those with LTBI could 
respond to both ESAT/CFP and PPE68 or just one of the two antigens, or neither. We 
postulated that those who respond to both ESAT/CFP and PPE68 have stronger immune 
responses to TB antigens, and could have different cytokine profiles from those who 
respond to either ESAT/CFP or PPE68 or neither. However, cytokine production after 2 
day PPD stimulation was comparable in all 4 groups (Fig 29A). The basal mRNA 
expression in unstimulated PBMCs was also comparable, with only small differences in 
IL10 and IL4 mRNA levels between ESAT+PPE68- and ESAT-PPE68+ groups 
(Fig 29B). Therefore, those responding to both ESAT/CFP and PPE68 did not have a 
distinct cytokine profile in response to PPD, so there was insufficient evidence to support 
the hypothesis that this group consists of people who have stronger immune recognition 
of mycobacterium proteins. 
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Figure 29. Cytokine profiles of ESAT+PPE68+, ESAT+PPE68-, ESAT-PPE68+ and ESAT-
PPE68- groups. In this graph, ESAT+ or ESAT- indicates positive or negative responses to 
overlapping peptides spanning ESAT-6/CFP-10 as described in Methods. 
(A) Cytokine production assessed by ELISA after 2 day PPD stimulation of PBMCs. (B) Basal 
cytokine mRNA expression in unstimulated PBMCs assessed by RT-PCR. Statistics by Mann  
Whitney U test, group medians are shown, error bars indicate 25th and 75th percentiles. 
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ESAT+PPE68+ and ESAT-PPE68+ groups had higher IFNγ responses to Ag85A and 
Acr2 than the other 2 groups (Fig 30). This is consistent with our earlier observation that 
the magnitude of PPE68 responses was correlated with Ag85A responses (Fig 8). Similar 
CD8+CD25+ as well as CD8+LAG3+ percentages was observed for all 4 groups (Fig 31). 
However, when the percentage of cells expressing CD107a, a degranulation marker, was 
examined, this was significantly higher in the ESAT+PPE68- group, relative to the 
ESAT-PPE68+ group (Fig 31). This suggests that the former group may have stronger 
cytotoxic responses against cells infected with live mycobacteria. 
 
Figure 30. Responses to Ag85A, Acr1 and Acr 2 in ESAT+PPE68+, ESAT+PPE68-, ESAT-
PPE68+ and ESAT-PPE68- groups. IFNγ production after 5 day stimulation of PBMCs with the 
mycobacterium antigens was assessed by ELISA. Statistics by Mann Whitney U test. *<0.05 
**<0.01. Group medians are shown, error bars indicate 25th and 75th percentiles. 
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Figure 31. Percentage of CD8+CD25+, CD8+LAG3+, CD107a+ cells in ESAT+PPE68+, 
ESAT+PPE68-, ESAT-PPE68+ and ESAT-PPE68- groups. PBMCs were stimulated with live 
BCG for 4 days, after which cells were washed, stained and analysed by flow cytometry, gated on 
lymphocytes. Statistics by Mann Whitney U test, group medians are shown, error bars indicate 
25th and 75th percentiles. 
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CHAPTER 5 DISCUSSION 
5.1 Selective mycobacterium antigen responses in ER, PPD+ENR and PPD-
ENR 
PPE68 and ESAT-6/CFP-10 are proteins found in the Mtb, but not the BCG, genome. 
However, not all ER responded to PPE68 (37.9%; Table 1A, B), and PPD+ENR had 
similarly high PPE68-stimulated IFNγ levels as ER subjects – almost half of PPD+ENR 
responded to PPE68 (Fig 7A and Table 1A). It is known that in the detection of LTBI, 
neither of these reagents has 100% sensitivity, particularly in TB-endemic areas. Studies 
have shown PPE68 sensitivity to be about 46% (Brock et al. 2004) and ESAT-6 between 
35%-100% (Ravn et al. 1999; Arend et al. 2000; Brock et al. 2001; Vekemans et al. 2001; 
Chapman et al. 2002; Mori et al. 2004; Meier et al. 2005; Ravn et al. 2005; Adetifa et al. 
2007; Kang et al. 2007). A main difficulty in interpreting sensitivity data with respect to 
LTBI lies in the lack of a gold standard for defining human LTBI; therefore all sensitivity 
data are based on culture-proven active TB cases, who may have different reasons (e.g. 
disease-induced anergy) for not responding to these Mtb proteins.  Nonetheless, it can be 
assumed that there is a proportion of people with LTBI not detected by either 
ESAT-6/CFP-10 or PPE68 alone. This could explain the lack of a statistically significant 
association between IFNγ responses induced by ESAT-6/CFP-10 and PPE68 (Table 2A). 
Therefore, sensitivity in LTBI detection would be raised by considering either PPE68+ or 
ESAT/CFP+ subjects to have LTBI – this was an alternative definition utilised in the 
second part of the analysis (Fig 23-31, Table 3). 
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The specificity of PPE68 peptides spanning amino acids 13 to 69 used in our present 
study is known to be comparable to ESAT-6 and CFP-10 (97%) based on a prior report 
(Brock et al. 2004). Based on this high specificity, almost all persons with positive IFNγ 
responses to PPE68 or ESAT-6/CFP-10 are likely to have LTBI. The small proportion 
who do not, are likely to be people with prior exposure to RD1-expressing environmental 
bacteria who have cross-reactive responses to PPE68 or ESAT-6/CFP-10 (Arend et al. 
2002; Meier et al. 2005). As such, the definition of LTBI group identified by PPE68 or 
ESAT-6/CFP-10 has high specificity but possibly less sensitivity, therefore we expect 
that some proportion of the LTBI-negative group could be undetected LTBI cases 
(false-negative). This limits the usefulness of these RD1 antigens in defining LTBI in our 
current study. 
 
Ag85 induces positive responses in a large proportion of healthy UK volunteers pre-BCG 
vaccination, increasing to almost 100% post-vaccination, and in 100% of LTBI subjects 
studied in Belgium (Huygen et al. 1988; Launois et al. 1994; Weir et al. 2008). In our 
population with almost universal BCG vaccination at birth, this high level of response 
was not observed. Only 21% of PPD+ENR (likely to be subjects with either prior 
environmental mycobacterial exposure or BCG vaccination), and 29% of ER (regarded as 
LTBI subjects) responded to Ag85A (Table 1A, B). This Ag85A response rate in the ER 
group is similar to another study of healthy, non-BCG-vaccinated Malawian subjects 
(Black et al. 2003). One likely explanation for the disparity in Ag85 response rate in 
different studies is the population differences in human leukocyte antigen haplotypes. 
With different human leukocyte antigen alleles, the antigen Ag85 epitopes could be more 
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effectively presented and recognised by T cells in some populations. If this is the case, 
then our findings suggest that Ag85A is not a sufficiently sensitive reagent for identifying 
subjects with mycobacterium exposure in Singapore. The significant positive correlation 
between the magnitude of PPE68 and Ag85A IFNγ responses in ER (Fig 8A), however, 
suggests that in LTBI, the Ag85A reactivity could be related to mycobacterium antigen 
load. 
 
Acr1 and Acr2 are latency-associated proteins expressed in Mtb upon infection of 
macrophages and when exposed to different environmental stressors (Yuan et al. 1996; 
Yuan et al. 1998; Stewart et al. 2002; Schnappinger et al. 2003; Voskuil et al. 2003). 
There was a correlation between Acr1 and Acr2 responses in ER, with a higher likelihood 
of response to both Acr1 and Acr2 in LTBI subjects (Table 2B, Fig 8B). Again, this 
suggests that Acr-reactivity is also likely to be related to mycobacterium antigen load. As 
Acr2 is induced following uptake of Mtb into quiescent mouse macrophages and Acr1 is 
only expressed in activated macrophages (Schnappinger et al. 2003), it could be possible 
both Acr1 and Acr2 are expressed when Mtb infects macrophages and the macrophages 
are subsequently activated. 
 
Similar to previous studies on latently infected individuals in UK and in the Netherlands 
(Wilkinson et al. 2005; Geluk et al. 2007), not all ER responded to Acr1 and Acr2 (21.9% 
and 37.5%; Table 1A). In addition, a smaller proportion of PPD+ENR responded to Acr1 
and Acr2 (16.7% and 25%; Table 1A). This contradicts a study which finds Acr1 to be a 
LTBI-specific marker (Geluk et al. 2007). Since Acr1 from Mtb is identical to Acr1 from 
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many other Mycobacterium species including BCG (reviewed in Section 2.5), it is 
unlikely to be LTBI-specific. Cross-reactive responses from exposure to environmental 
mycobacteria or BCG vaccination would explain the lack of specificity of this protein. 
The observations of Geluk could be because such exposures may be relatively rare in the 
locality where their study was conducted. Likewise, Mtb Acr2 is identical to BCG Acr2, 
and highly similar to Acr2 in other environmental mycobacteria such as M. avium and 
M. smegmatis (reviewed in Section 2.5). Cross-reactive immune responses to Mtb Acr2 
has been described in M. bovis infected humans and cattle (Wilkinson et al. 2005). Thus, 
cross-reactive immune responses to Mtb Acr2 generated by BCG or other environmental 
bacteria probably accounts for 25% of Acr2 responders in PPD+ENR (Table 1A). It is 
evident that Acr1 or Acr2 reactivity alone lacks sufficient specificity for defining LTBI. 
However, in PPD+ENR subjects, a response to Acr1 and Acr2 could be an indicator of 
LTBI, since half or more of Acr1 and Acr2 responders in the PPD+ENR group also 
responded to PPE68 (50% and 66.7%; data not shown). This could be an additional assay 
used to increase the sensitivity of LTBI detection based on RD1 antigens. 
 
5.2 IL4 and IL10 associated with LTBI (ER) 
Th2 cytokines are known to be elevated in TB patients (Seah et al. 2000; Hussain et al. 
2002; Lee et al. 2003; Dheda et al. 2005). Studies in the Gambia and Ethiopia suggest 
that IL4 is elevated in ESAT-6 positive healthy people relative to ENR (Fletcher et al. 
2004; Demissie et al. 2006). TB patients have significantly higher levels of the 
immunosuppressive cytokine IL10 than ESAT-6 positive subjects (Demissie et al. 2004), 
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this may be related to the need to suppress excessive inflammatory responses in TB 
(Boussiotis et al. 2000). 
 
It is interesting to note that our PPD+ENR group had the highest basal IL10 mRNA 
expression and the lowest levels of IL4 mRNA (Fig 9B), the opposite was noted for LTBI 
(ER) group. Furthermore, IL10 mRNA levels were not correlated with IL4 in PPD+ENR 
(Fig 10B), and were only positively correlated in ER (Fig 10A-C). The distinct difference 
between LTBI (infected) and PPD+ENR (not infected) in their profiles for these two 
cytokines suggests that these responses are related to the latent infection. It is possible 
that in latently infected individuals, those with higher levels of IL4 expression have a 
higher bacterial load, since this cytokine expression has been linked to risk of reactivation 
in LTBI (Wassie et al. 2008) and their higher IL10 expression levels may reflect the same 
trend. It was noted that the inter-group differences seen in unstimulated IL10 expression 
was not seen in the PPD-stimulated response (Fig. 9). This is not unusual because PPD is 
a powerful Th1 stimulant and tends to downregulate IL10 production, at least within a 
2-day stimulation assay, and it was because of this tendency that the unstimulated 
cytokine profiles were concurrently assessed. 
 
IL10 inhibits pro-inflammatory cytokine production in monocytes and macrophages (de 
Waal Malefyt et al. 1991). Phagocytosis of Mtb induces maximal IL10 secretion in 24 
hours (Shaw et al. 2000), thus Mtb may also induce IL10 production directly upon 
infection of macrophages, concurrent with the production of pro-inflammatory cytokines 
(Wallis et al. 1990). A significant positive correlation between PPD-stimulated IL10 and 
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the pro-inflammatory cytokines IL6 and TNFα was observed in latently infected subjects 
(Fig 11A, B) as well as in ENR (data not shown). This suggests that PPD is a powerful 
stimulant of inflammatory processes, the magnitude of which corresponds to the level of 
suppressive cytokine production required. This is further supported by observations in 
both ER and ENR groups, that expression of the two pro-inflammatory cytokines, IL6 
and TNFα were positively correlated (Fig 12A), as were TNFα and IFNγ production 
(Fig 12B), indicating that these cytokines act in concert with each other during the 
inflammatory process induced by PPD. 
 
5.3 Regulatory cytokines in response to Th1 responses in LTBI 
Protective immunity to TB is mainly dependent on Th1 immune responses, which results 
in activation of macrophages and subsequent killing of intracellular Mtb (O'Garra 1998; 
Glimcher and Murphy 2000). IL12 and IL18 are two Th1 related cytokines that synergise 
for maximal IFNγ production from Th1 cells (Okamura et al. 1998). Consistent with this, 
IL12p35 mRNA expression was positively correlated with IFNγ expression only in 
latently infected individuals (Fig 15A). However, IL18 mRNA levels were not (Fig 15B). 
We surmised that in our LTBI cohort, IL12 could be the main inducer of IFNγ. With the 
demonstration of the requirement of IL12 in maintenance of effector or memory Th1 
cells against TB (Stobie et al. 2000), it is logical that IL12 has a significant protective 
role in ER subjects with persistent latent Mtb by inducing protective, long lasting Th1 
immune responses and therefore preventing progression to active TB. With regards to 
IL18, not only was its expression not correlated with IFNγ mRNA expression, IL18 
mRNA levels were positively correlated with IL4 in both latently infected and uninfected 
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groups (Fig 16B). This indicates IL18 may play a part in the stimulation of general 
non-specific Th2 responses instead of Th1 responses – it has previously been found that 
IL18 may induce Th2 cytokine production in the absence of IL12, distinct from its Th1 
polarising ability in the presence of IL12 (Nakanishi et al. 2001). 
 
In the presence of a robust Th1 immunity, regulatory cytokines may be required to limit 
inflammation. Host immune-modulation by Mtb may also be mediated by IL10, which 
inhibits IL12 production by dendritic cells, resulting in a lower Th1 response (Demangel 
et al. 2002). However, no direct correlation was observed between regulatory cytokines 
IL10 or TGFβ, and IFNγ or IL12 in ER subjects (data not shown), with the exception of a 
positive correlation observed between TGFβ and IL12p35 mRNA levels (Fig 13C). Since 
IL12p35 is associated with IFNγ production in this cohort (Fig 15A), TGFβ may limit 
Th1 responses through the regulation of IL12 in LTBI. However, it does not regulate 
IL18 responses in such people as IL18 mRNA expression in the ER group was correlated 
with IL10 mRNA expression, but negatively correlated with TGFβ mRNA expression 
(Fig 13A, B). This means that in the latently infected people, high IL18 levels are 
associated with high IL10 levels and low TGFβ levels, although it is known that IL10 and 
TGFβ have overlapping immunosuppressive functions (Wahl 1992). In vitro studies show 
that both IL10 and TGFβ are induced upon stimulation of dendritic cells with Mtb cell 
extract (Balkhi et al. 2004; Latchumanan et al. 2005) and are synergistic in the 
suppression of IFNγ response (Othieno et al. 1999). However, this synergism was not 
seen in our ER (LTBI) cohort (Fig 14) in contrast to the upregulation of both regulatory 
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cytokines observed in TB patients (Olobo et al. 2001). This may be due to the lower 
levels of Mtb-induced inflammation in LTBI. 
 
5.4 CD8 Tregs and CD4+CD25+ natural Tregs in LTBI 
Tregs are implicated in infectious diseases, especially in chronic infections, where they 
prevent excessive inflammation and immunopathology, but also promote pathogen 
persistence (Belkaid and Rouse 2005). TB antigen-specific CD4+CD25+ Tregs are 
increased at site of infection as well as in the blood of TB patients, and CD8+CD25+ 
Tregs can be induced by M. bovis BCG (Guyot-Revol et al. 2006; Ribeiro-Rodrigues et al. 
2006; Chen et al. 2007; Joosten et al. 2007). Majority of this CD8 Treg population 
induced upon BCG stimulation express both LAG3 and CD25 (Joosten et al. 2007). 
Similar to the trend observed for IL10 mRNA levels in Fig 9B, both CD8+CD25+ Tregs 
and CD8+LAG3+ Tregs in ER were significantly higher than PPD-ENR (Fig 17). These 
results indicate that CD8 Tregs are indeed induced in ER. However, it is not clear 
whether these Tregs are induced by Mtb with further expansion upon BCG stimulation or 
are only induced upon BCG stimulation. Given that mycobacterial fraction-activated 
CD8 T cells have immunosuppressive activity and regulatory CD8 T cells can be found 
in TB patients (Sussman and Wadee 1992; Yu et al. 2007), the former seems to be more 
likely. 
 
Median PPD-stimulated IFNγ levels were two-fold higher in ER than PPD+ENR (data 
not shown), indicating a stronger effector Th1 response in ER. As such, we expected that 
ER group should have the highest proportion of CD8 Tregs among the three groups. 
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Instead, PPD+ENR had slightly higher CD8 Treg proportion than ER (Fig 17). Due to the 
high degree of variability inherent in each group, these data need to be interpreted with 
caution. It is currently not clear if CD8 Tregs are a negative factor in the mycobacterium 
response, and whether they imply any inherent susceptibility. However, it has been 
suggested that CD8+CD25+ Tregs may mediate immunosuppression via the chemokine 
CCL4 in TB (Joosten et al. 2007). In agreement with the undetectable IL10 and TGFβ 
levels following CD8 Treg induction in that study (Joosten et al. 2007), we also found no 
correlation between proportion of CD8+CD25+ Tregs and the two cytokines (Fig 18A, B), 
suggesting immunosuppression by this CD8 Treg subset may not be mediated by these 
two regulatory cytokines. Consistent with Joosten’s finding that CD8+CD25+ cells also 
express FoxP3, the proportion of CD8+CD25+ cells was positively correlated with basal 
FoxP3 expression in ER (Fig 18C), supporting the probability that in our latently infected 
healthy subjects, these cells express Foxp3 and have Treg activity. It appears that 
CD8+CD25+ Treg production could be responding to pro-inflammatory cytokines in 
PPD+ENR, but this was not seen in the LTBI cases (Fig. 19). 
 
The proportion of natural CD4+CD25+ Tregs in latent TB has not previously been 
investigated. Though no significant differences were observed between ER, PPD+ENR 
and PPD-ENR, the trend for CD4+CD25+ Tregs mirrored that of CD8+CD25+ Tregs (Fig 
20). Non-significant p values were most likely due to small group sizes, which were 
limited by the amount of remaining patient samples for the CD4+CD25+ assay. 
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CD4+CD25+ Tregs may have a role in the regulation of pro-inflammatory cytokine IL6 
and TNFα production as well as Th2 cytokine IL4 production in Mtb infection since 
significant negative correlations between the proportion of CD4+CD25+ Tregs and these 
cytokines were seen in ER (Fig 21A-C). A mechanism for CD4+CD25+ Treg 
immunosuppression in humans has been demonstrated, whereby CD4+CD25+ Tregs shed 
TNF receptors leading to the inhibition of TNFα action and subsequent inhibition of 
lipopolysaccharide-induced IL6 production (van Mierlo et al. 2008). Another possible 
explanation for the negative correlation between IL6 and natural CD4 Tregs could be due 
to the influence of IL6 on CD4+CD25+ Tregs. In a mouse model of colitis, signalling 
through the IL6 receptor prevents de novo induction of inducible CD4 Tregs from naïve 
CD4+CD25- T cells (Dominitzki et al. 2007). A similar situation may plausibly occur in 
LTBI. 
 
In our study, the proportions of CD4+CD25+ Tregs and CD8+CD25+ Tregs in live 
BCG-stimulated cells were positively correlated in the whole study cohort (Fig 22A). 
CD8+CD25+ Tregs could be a source of IL10 in the general population as their 
proportions were correlated positively with IL10 mRNA expression in the total study 
cohort (Fig 22B, C), even though this was not noted for ER group alone (Fig. 18A). 
Immunosuppression by CD4 Tregs is mainly mediated by cell-cell contact, by signalling 
through cytotoxic T lymphocyte antigen 4 expressed on Treg surfaces (Read et al. 2000; 
Nakamura et al. 2001), rather than by immunosuppressive cytokines such as IL10. 
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5.5 Acr2 reactivity identifies LTBI subjects with distinct immune profiles 
Acr2-specific T cells have been previously demonstrated to be increased in those with 
recently acquired latent infection (Wilkinson et al. 2005). While there were significant 
positive correlations between PPE68 and Ag85A responses in both LTBI groups 
(Fig 24A, B), the correlation coefficient was higher in the recently exposed group. This is 
biologically consistent with the likelihood that in recently infected people, responses to 
Mtb antigens are due to the same antigenic source. Moreover, the recently exposed LTBI 
cases mounted stronger Th1 responses (IL12p35 and IFNγ) which were correlated 
(Fig 25B, Fig 26). Taken together, the cytokine and mycobacterium antigen response 
profile supports the probability that Acr2 distinguishes remotely exposed from recently 
exposed LTBI cases amongst healthy subjects with no documented TB contact. This is 
likely to be a valuable aid to screening subjects for mycobacterium exposure prior to TB 
vaccine studies. 
 
5.6 Association of antigen reactivity patterns with immune responses 
characteristic of LTBI 
Our work has provided evidence that LTBI subjects have stronger inflammatory as well 
as regulatory cytokine responses than ENR. We therefore hypothesised that LTBI 
subjects who responded to multiple mycobacterial antigens (Ag85A+Acr2+) might 
represent those with higher bacterial burdens and may have responses which were more 
polarised towards these characteristics. However, cytokine production and mRNA 
expression was comparable between Ag85A+Acr2+ LTBI and Ag85A-Acr2- LTBI 
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subjects (Fig 28A, B). This may partly be because of the limited reactivity to Ag85A in 
our population as discussed earlier, or because those with high bacterial burdens do not 
necessarily respond to these two antigens. The alternative of using double-positive 
ESAT/CFP+PPE68+ responses was also tested, but this also did not differentiate LTBI 
subjects with strong cytokine and Treg responses from those with weak responses (Fig 29, 
Fig 31). One reason could be that positive reactivity to multiple mycobacterium antigens 
may not be directly due to high levels of Mtb antigen exposure. Additionally, since most 
immunological differences between ER and ENR subjects are likely to be related to the 
latent infection in ER subjects, further differentiation between different sub-groups 
within the LTBI group may require a study on a much larger cohort of such persons. 
 
5.7 Conclusion and future work 
Prior to this work, rates of TB-specific antigen responses in LTBI subjects and how 
expression of the different cytokines are related in such subjects have not previously been 
studied. This present study has demonstrated that in LTBI, there is a balance of pro- and 
anti-inflammatory responses, the latter being potentially regulated by Tregs. IL10 and 
CD4+CD25+ Treg responses were associated with PPD-specific IL6 and TNFα responses, 
and IL12p35 was correlated with TGFβ expression. Thus, TGFβ or IL10 may limit 
inflammatory responses through the regulation of IL12, IL6 and TNFα in LTBI. The 
CD8+ Tregs could be a source of IL10 as their levels were correlated.  In the LTBI study 
cohort, the IFNγ production was likely to be induced by IL12p35, but not IL18. This 
work is also the first to show that clinically healthy subjects – often regarded as a 
homogenous cohort in many TB immunity studies – exhibit a wide range of immune 
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responses to Mtb antigens. More importantly, their response patterns may enable 
stratification of the TB immunity levels of such persons. We found that immune 
reactivity to some of these antigens identified further immunologically distinct groups 
amongst those with LTBI – Acr2-reactivity, for example, identified a sub-group with 
higher IL12p35 and IFNγ mRNA levels as well as higher CD8 Tregs correlated with 
Foxp3 expression. These are responses characteristic of active TB infection and thereby 
support the use of Acr2 as a marker of recently acquired latent infection. However, in 
contrast to some other populations, Ag85A response rates were exceptionally low in our 
study population and unlikely to be useful in identifying mycobacterium-sensitised 
persons. 
 
In future work, reactivity to other mycobacterium antigens should be tested for their 
efficacy in differentiating between LTBI with protective or non-protective immunity. For 
instance, other proteins expressed under the control of DosR regulon are of interest 
because this regulates expression of proteins essential for Mtb survival in latency. 
Therefore, people with strong T cell responses to these antigens are likely to be able to 
respond well to latent infection. The most promising DosR regulon encoded antigens 
include Rv1733c, Rv2029c, Rv2627c and Rv2628 which have been identified as the most 
frequently recognised antigens in TST+ individuals or latently infected people (Leyten et 
al. 2006). However, it remains to be tested if LTBI subjects segregated based on 
reactivity to DosR-regulated antigens are distinct in their cytokine profile. 
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 To find out if LTBI cases can be accurately detected by using either PPE68 or 
ESAT-6/CFP-10 reactivity in defining LTBI, recent TB household contacts with known 
exposure should be tested with these antigens, and long term follow-up undertaken to 
determine disease reactivation rates. If the risk of reactivation is the same for both single 
positive and double positive groups (PPE68+ and ESAT/CFP+), this would suggest that 
PPE68 and ESAT-6/CFP-10 are both able to identify people with LTBI. 
 
Given that the Ag85A response rate in our cohort was exceptionally low for the levels of 
PPD-reactivity (29.2% in ER and 21.1% in PPD+ENR; Table 1) the possibility that this 
low response could be due to different recognition frequencies of human leukocyte 
antigen haplotypes in our cohort compared with other study cohorts could be explored by 
epitope mapping for Ag85A in relation to different human leukocyte antigen haplotypes 
in our population. 
 
From the correlations between IL12p35, IL18 and IFNγ in the LTBI group (Fig 15A, B), 
it was surmised that IL12 may induce IFNγ production, while IL18 was paradoxically 
associated with induction of Th2 responses (Fig 16B). A different in vitro assay of 
lymphocyte-dependent mycobactericidal activity could be performed by infecting 
PBMCs of LTBI subjects, with or without prior anti-IL12 or anti-IL18 treatment, and 
measuring intracellular mycobacterium survival as well as the level of IFNγ and IL4 
production. Such an assay would help to identify whether there is functional inhibition on 
mycobacterium growth related to these cytokines. 
 
 118
The relatively low frequency of Tregs in our study cohort is likely to be because this 
group did not have a defined TB exposure. To further investigate Treg responses in LTBI, 
a cohort of TB household contacts with recent exposure would provide a better 
opportunity to study these cells. Enrichment of Tregs using anti-CD25 positive selection 
before analysis by flow cytometry may increase sensitivity of the Treg assay. Other Treg 
markers, such as cytotoxic T lymphocyte antigen 4, glucocorticoid-induced TNF receptor, 
CD45RO should also be used to further characterise Tregs in these subjects. 
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CHAPTER 7 APPENDIX 
7.1 Primers for amplifying target genes for cloning 
Primer sequences with restriction enzyme site added (underlined) Product size (bp) 
Acr1  
Forward primer with NcoI site added 
5’-GGCCCCATGGCGATGGCCACCACCCTTCCC-3’ 
 





Forward primer with BamHI site added 
5’-GCCGGATCCATGAACAATCTCGCATTGTGGTC-3’ 
 





7.2 Preparation of solutions for plasmid extraction (‘mini-prep’) 
7.2.1 Resuspension solution (500 ml) 
25 ml of 1M Tris HCl, pH 7.5 
10 ml of 0.5 M EDTA, pH 8.0 
 
Topped up with distilled water and autoclaved at 121°C for 15 minutes. 
50 mg of RNase added prior to use. 
 
7.2.2 Cell Lysis solution (500 ml) 
10 ml of 10M NaOH 
50 ml of 10% SDS 
 
Topped up with distilled water. 
 
7.2.3 Neutralisation solution (500 ml) pH 4.8 
64.722 g of potassium acetate 
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Dissolved in distilled water and pH adjusted using glacial acetic acid. 
Topped up to 500 ml with distilled water and autoclaved at 121°C for 15 minutes. 
 
7.3 Primers for sequencing 
Primer sequences 
Forward primer (T7 promoter) 
5’-TAATACGACTCACTATAGGG-3’ 
 




7.4 Preparation of protease inhibitor, 50x 
0.1 ml of 5 mg/ml aproptinin (500 μg/ml final) 
0.5 ml of 1 mg/ml leupeptin (500 μg/ml final) 
0.1 ml of 5 mg/ml pepstatin (500 μg/ml final) 
0.1ml of 0.5 M PMSF (50mM final) 
 
Topped up to 1 ml with ethanol and stored at -80°C. Protease inhibitor was used at 
working concentration of 1x. 
 
7.5 Preparation of FPLC buffers 
7.5.1 Lysis Buffer (500 ml) pH 8.0 
3.9 g NaH2PO4 (50mM final) 
8.77 g NaCl (300mM final) 
0.34 g imidazole (10mM final) 
 
Buffer adjusted to pH 8 with 1M NaOH, topped up to 500 ml with nanopure water and 
filtered (to de-gas buffer) before use. 
 
7.5.2 Wash Buffer (200 ml) pH 8.0 
1.56 g NaH2PO4 (50mM final) 
3.51 g NaCl (300mM final) 
0.27 g imidazole (20mM final) 
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Buffer adjusted to pH 8 with 1M NaOH, topped up to 200 ml with nanopure water and 
filtered (to de-gas buffer) before use. 
 
7.5.3 Elution Buffer, 150mM imidazole (100 ml) 
0.78 g NaH2PO4 (50mM final) 
1.75 g NaCl (300mM final) 
1.02 g imidazole (150mM final) 
 
Buffer adjusted to pH 8 with 1M NaOH, topped up to 100 ml with nanopure water and 
filtered (to de-gas buffer) before use. 
 
7.5.4 Elution Buffer, 250mM imidazole (100 ml) 
0.78 g NaH2PO4 (50mM final) 
1.75 g NaCl (300mM final) 
1.7 g imidazole (250mM final) 
 
Buffer adjusted to pH 8 with 1M NaOH, topped up to 100 ml with nanopure water and 
filtered (to de-gas buffer) before use. 
 
7.6 Preparation of reagents for SDS-PAGE 
7.6.1 Separating gel (12%) 
6.6 ml nanopure water 
8.0 ml 30 % acrylamide/ 0.8 % bisacrylamide 
5.0 ml 1.5M Tris HCl (pH 8.8) 
200 μl 10% SDS 
200 μl 10% ammonium persulfate 
8 μl tetramethylethylenediamine (TEMED) 
 
Isopropanol was added to the top of the molten gel to isolate gel from air during casting. 
 
7.6.2 Stacking gel (4%) 
6.1 ml nanopure water 
1.3 ml 30 % acrylamide/ 0.8 % bisacrylamide 
2.5 ml 0.5M Tris HCl (pH 6.8) 
100 μl 10% SDS 
100 μl 10% ammonium persulfate 
10 μl tetramethylethylenediamine (TEMED) 
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Isopropanol on top of polymerised separating gel was removed prior to the overlaying of 
gel mixture on top. Well comb was carefully inserted. 
 
7.6.3 SDS loading buffer, 6x (10 ml) 
7 ml 0.5M Tris HCl (pH 6.8) 
3 ml glycerol (30% final) 
1 g SDS (10% final) 
0.93 g DTT (0.6M final) 
1.2 mg bromophenol blue (0.012% final) 
 
Topped up with distilled water, aliquoted and stored at -80°C. 
 
7.6.4 Running Buffer, 5x (1000 ml) pH 8.3 
3 g Tris-base 
14.4 g glycine 
10 ml 10% SDS 
 
Topped up with nanopure water to prevent precipitation. Running buffer used at 1x and 
diluted with nanopure water 
 
7.6.5 Coomassie Blue Staining solution (1000 ml) 
100 ml acetic acid 
200 ml methanol 
0.2 g Coomassie blue 
 
Topped up with distilled water and filtered. 
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7.6.6 Gel Destaining solution (1000 ml) 
100 ml acetic acid 
200 ml methanol 
 
Topped up with distilled water. 
 
7.7 Preparation of reagents for Western Blot 
7.7.1 Transfer Buffer, 5x (1000 ml) pH 8.3 
29 g Tris-base 
145 g glycine 
5.0 g SDS 
 
Topped up with distilled water and autoclaved at 121°C for 15 minutes. 
 
1x Transfer Buffer was prepared by adding 200 ml of 5x Transfer Buffer to 200 ml of 
methanol and made up to 1000 ml with distilled water. Buffer was prepared fresh prior to 
use. 
 
7.7.2 Tris buffered saline – 0.05% Tween 20, TBS-T (1000 ml) 
100 ml of 1M Tris HCl, pH 7.6 
30 ml of 5M NaCl 
10 ml of 10% Tween-20 
 
Topped up with distilled water and autoclaved at 121°C for 15 minutes. 
 
7.8 Peptide sequences for antigens used in PBMC stimulation 
7.8.1 ESAT-6/CFP-10 







































Peptide number Sequence 
PPE68 pep2 ARLMAGAGPAPMLAAAA 
PPE68 pep3 PMLAAAAGWQTLSAALD 
PPE68 pep4 TLSAALDAQAVELTARL 
PPE68 pep5 VELTARLNSLGEAWTGG 
PPE68 pep6 GEAWTGGGSDKALAAAT 
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7.9 Preparation of FAC (triple supplement), 10x  
25 mg ferric ammonium citrate (50 μg/ml final) 
1 g sodium glutamate (0.2 % final) 
1 g L-asparagine (0.2 % final) 
 
Made up with 50 ml of nanopure water, filter sterilised and stored at 4°C in the dark. 
 
7.10 Cytokine primers for RT-PCR 























































































Forward: 5’- TGCTCCAGAAGGCCAGACAA -3’ 
Reverse: 5’-CTCCACCTGGTACATCTTCA-3’ 
 






























































































































7.11 PCR conditions for each cytokine 
7.11.1 General PCR conditions 
Initial denaturation: 95°C for 5 minutes 
 
Optimised number of cycles of: 
95°C for 30 seconds 
Optimised annealing temperature for 30 seconds 
72°C for 45 seconds 
 
Final elongation: 72°C for 10 minutes 
 






















IL4 60°C 30 60°C 20 60°C 25 
IL6 50°C 35 50°C 20 50°C 28 
IL10 66°C 40 60°C 21 60°C 25 
IL12p35 55°C 35 64.5°C 18 60°C 28 
IL18 55°C 35 55°C 18 55°C 26 
IFNγ 60°C 30 60°C 20 60°C 25 
TGFβ 68°C 35 55°C 30 60°C 20 
FoxP3 50°C 45 50°C 19 50°C 26 
 
